



---

State Demonstrations Group

**DEC 06 2017**

David Simnitt  
Interim Medicaid Director  
Oregon Health Authority  
500 Summer Street Northeast, E-15  
Salem, OR 97301

Dear Mr. Simnitt:

The Centers for Medicare & Medicaid Services (CMS) has reviewed the proposed interim technical changes to Oregon's section 1115 demonstration, entitled Oregon Health Plan Demonstration (Project Numbers: 21-W00013/10 and 11-W00160/10). Specifically, Oregon requested approval of the biennial update to the Prioritized List.

CMS has reviewed the changes reflected in the biennial update and have determined that the State's biennial updates to the Prioritized List are valid technical changes designed to ensure that the List is medically accurate, cost-effective, and reasonable. Therefore, we are approving the Prioritized List, effective January 1, 2018. This approval does not alter any of the requirements specified in the STCs of the demonstration.

If you have any questions, please contact your project officer, Ms. Linda Macdonald. Ms. Macdonald can be reached at (410) 786-3872, or by email at [Linda.Macdonald@cms.hhs.gov](mailto:Linda.Macdonald@cms.hhs.gov).

We look forward to continuing to work with you and your staff.

Sincerely,

A black rectangular box redacting the signature of Kim Howell.

Kim Howell  
Director  
Division of State Demonstration and Waivers

cc: David Meacham, ARA Seattle Regional Office

May 2017

# >> Prioritization of Health Services

A Report to the Governor and the 79th Oregon Legislative Assembly



Oregon  
Health  
Authority  
HEALTH POLICY & ANALYTICS

Health Evidence Review Commission  
Health Policy and Analytics  
Oregon Health Authority

2017

# Contents

|   |    |
|---|----|
| » Executive summary.....  | IV |
| » Charge to the Health Evidence Review Commission.....                                  | 1  |
| » The prioritization methodology .....  | 3  |
| » Biennial review of the Prioritized List.....  | 5  |
| » Review of the treatment and prevention of obesity.....                                | 7  |
| » Prioritization of services with low importance .....                                  | 8  |
| » Other biennial review changes.....  | 9  |
| » Interim modifications to the Prioritized List .....                                   | 11 |
| » Recommendations .....   | 12 |
| » Appendix A: Commission and subcommittee membership.....                               | 13 |
| » Health Evidence Review Commission members .....                                       | 13 |
| » Value-based Benefits Subcommittee members.....  | 14 |
| » HERC staff.....   | 15 |
| » Appendix B: Biennial review changes .....   | 16 |
| » Changes related to the review of the treatment and<br>prevention of obesity.....      | 16 |
| » Changes related to the prioritization of health services<br>with low importance ..... | 20 |
| » Appendix C: Prioritized health services.....  | 23 |
| » Frequently asked questions: A user's guide to the<br>Prioritized List.....            | 23 |
| » Line descriptions for the 2018–19 Prioritized List of<br>Health Services.....         | 25 |

|  |           |
|--|-----------|
| » Statements of intent and guideline descriptions for<br>the 2018–19 Prioritized List of Health Services ..... | 47        |
| » <b>Appendix D: Evidence-based reports</b> .....  | <b>53</b> |

# Executive summary

The “2018–19 Prioritized List of Health Services” (aka “Prioritized List”) (see Appendix C) shows the final line rankings as approved by the Health Evidence Review Commission (HERC) when it completed the biennial review of the list at its March 9, 2017 meeting.

The focus of this biennial review has been on a comprehensive look at the evidence on the treatment and prevention of obesity. Good evidence was found for the expansion of bariatric surgery for adults with a BMI  $\geq 35$  with serious comorbidities beyond type 2 diabetes mellitus, which has been funded since 2008. The evidence showed lower mortality rates and a reduction in major adverse cardiovascular events, outweighing the risks of surgery. Additionally, significant reductions in BMI, type 2 diabetes and hypertension were seen. Even greater benefits were seen in adults with BMI  $\geq 40$ , regardless of comorbidities, leading to a higher prioritization for the treatment of that population as well. Unfortunately, the evidence did not show significant benefits for the use of prescription drugs or devices such as inflatable balloons; as a result, those treatments are not included in the funded region. The review also led to modest expansions in already covered behavioral interventions such as cognitive behavioral therapy. For more detail on the review of obesity treatments, see pages 7–8 of the report and Appendix B.

Another significant change resulting from this biennial review is including two new lines on the Prioritized List relating to the prioritization of services with marginal clinical benefit and/or low cost-effectiveness (line 500) and those with no clinically important benefit or that have harms that outweigh benefits (line 660). These lines, along with two associated guidelines, will more transparently allow the prioritization of condition-treatment pairings that historically have not appeared on the Prioritized List. The use of the guideline notes will identify both procedures and therapies that have CPT and HCPCS codes as well as those that don’t, such as prescription drugs. A new statement of intent provides a list of general criteria that could result in prioritizing a service on one of these new lines. See pages 8–9 of the report and Appendix B for further detail.

In the process of maintaining the Prioritized List over the last two years, the HERC produced four sets of interim modifications forwarded to the president of the Oregon Senate and speaker of the House of Representatives. This included the definition of several new guideline notes and the revision or removal of a number of previously existing guidelines (see Appendix C for a listing of all statements of intent and guideline notes). Oregon Health Authority’s Actuarial Services Unit determined that

none of the interim modifications made from October 2015 through January 2017 have a significant fiscal impact requiring presentation to the Oregon Legislative Emergency Board.

The Health Evidence Review Commission appreciates the opportunity to continue its work on health care prioritization in order to provide the most beneficial, cost-effective services to Oregon's Medicaid population.

# Charge to the Health Evidence Review Commission

HB 2100 (2011) established the Health Evidence Review Commission (HERC) in part to:

“[D]evelop and maintain a list of health services ranked by priority, from the most important to the least important, representing the comparative benefits of each service to the population to be served.”\*

As it performs this work, HERC is also directed to:

“[C]onsider both the clinical effectiveness and cost-effectiveness of health services, including drug therapies, in determining their relative importance using peer-reviewed medical literature...”†

HERC is composed of 13 members. There are five physicians (including one doctor of osteopathy and one hospital-based physician), two consumer representatives, a public health nurse, a behavioral health representative, a dentist, a complementary and alternative medicine provider, a pharmacy representative and a health insurance representative. HERC relies heavily on input from its subcommittees and ad hoc advisory panels. The HERC’s Value-based Benefits Subcommittee (VbBS) reviews all potential changes to the Prioritized List. VbBS has both Commission members and other provider and stakeholder representatives.‡ An Oral Health Advisory Panel, Behavioral Health Advisory Panel and Genetics Advisory Panel provide recommendations on new codes and issues specific to their areas of expertise.

HERC’s Prioritized List is composed of condition-treatment pairs of diagnosis and treatment codes used to define the services represented. As of Oct. 1, 2015, the conditions on the list are represented by the coding nomenclature of the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). Medical treatments are listed using codes from the American Medical Association’s Current Procedural Terminology (CPT), the American Dental Association’s Current Dental Terminology (CDT) and the Healthcare Common Procedure Coding System (HCPCS).

Appropriate diagnostic services are covered under OHP whether or not the final diagnosis appears in the funded region of the Prioritized List. Only after the

---

\* *Oregon Revised Statutes (ORS) 414.690(3).*

† *ORS 414.690(4)(c).*

‡ *A list of the Commission and VbBS membership can be found in Appendix A.*



diagnosis has been established is the list used to determine whether further treatments are covered under the plan. Therefore, diagnosis codes representing signs and symptoms and procedures codes for diagnostic procedures are not included on the list. Another service covered regardless of the underlying condition is palliative care, as described by the first of three statements of intent associated with the Prioritized List.

Procedure codes representing appropriate ancillary services such as prescription drugs, durable medical equipment or services such as the removal of sutures are intended to be covered if the condition they are being used to treat lies in the funded region. Because of the volume of codes that represent ancillary services and the fact that they are often associated with many different diagnoses, these codes do not appear on the list. In some cases, HERC has created guideline notes for specific ancillary and diagnostic services to clarify its evidence-informed intent for coverage of these services.

In addition, other procedure codes represent services not added to the list because they are not appropriate for coverage. These include codes for experimental treatments or cosmetic services. Diagnosis codes that are non-specific or do not identify a health condition or disease process are also not included on the Prioritized List.

The Health Systems Division maintains electronic files to account for codes not appearing on the list and to ensure appropriate fee-for-service reimbursement. OHP providers and contracted coordinated care organizations (CCOs) have web-based access to the information in these electronic files through the Medicaid Management Information System (MMIS) so that service coverage is as uniform as possible.

Regarding the potential impact of changes to the Prioritized List, HERC is considering that HERC staff consult with staff from the Oregon Health Authority's Health Systems Division, Analytics Unit, and Actuarial Services Unit to determine the magnitude of the potential impact to program cost and administrative burden. This information is shared with HERC during its decision making process as appropriate. This information can also play a role in timing implementation of a list change in order to make any necessary adjustments to the CCO contracted rates and/or ensure ample time for operationalizing the change.

# The prioritization methodology

HERC continues to use the prioritization methodology in place since 2008. Each line item on the Prioritized List is assigned to one of eight broad health care categories that establish a basic framework for the list (shown on next page as Figure 1). Once the line items have been assigned to one of the categories, a list of criteria is used to sort them within the categories (shown as Figure 2, with the range of scores shown in parentheses). These measures are felt to best capture the impacts on both individuals' and the population's health that HERC believes are essential in determining the relative importance of a condition-treatment pair.

Since not every service in category 1 is more important than every service in category 2 and so on, a weight is applied to each category that is multiplied by the total criteria score for each condition-treatment pair. The category weights are shown in parentheses after the title for each category in Figure 1. A total score is then calculated for each line using the formula shown in Figure 3 to sort all line items, with the lowest net cost used to break any ties. HERC then applied hand adjustments where the application of this methodology did not result in a ranking that reflected the importance of the service, which was the case for just 3% of the line items.

Services near the top of the list as a result of this methodology include:

- Maternity care and newborn services;
- Preventive services found to be effective by the U.S. Preventive Services Task Force; and
- Treatments for chronic diseases where ongoing maintenance therapy can prevent exacerbations of the disease that lead to avoidable, high-intensity service utilization, morbidity and death. Examples of these diseases include diabetes, major depression, asthma and hypertension.

Figure 1: Rank order of health care categories

1. Maternity & Newborn Care (100)
2. Primary Prevention and Secondary Prevention (95)
3. Chronic Disease Management (75)
4. Reproductive Services (70)
5. Fatal Conditions, Where Treatment is Aimed at Disease Modification or Cure (40)
6. Nonfatal Conditions, Where Treatment is Aimed at Disease Modification or Cure (20)
7. Self-limiting Conditions (5)
8. Inconsequential Care (1)

Figure 2: Population and individual impact measures

1. Impact on Healthy Life (0 to 10)
2. Impact on Suffering (0 to 5)
3. Population Effects (0 to 5)
4. Vulnerability of Population Affected (0 to 5)
5. Tertiary Prevention (0 to 5)
6. Effectiveness (0 to 5)
7. Need for Medical Services (0 to 100%)
8. Net Cost (0 to 5)

Figure 3: Prioritization formula

$$\begin{array}{l} \text{Category Weight} \end{array} \times \begin{array}{l} \text{Impact on Healthy Life} \\ + \text{Impact on Suffering} \\ + \text{Population Effects} \\ + \text{Vulnerability of} \\ \text{Population Affected} \\ + \text{Tertiary Prevention} \\ \text{(categories 6 \& 7 only)} \end{array} \times \text{Effectiveness} \times \text{Need for Service}$$

# Biennial review of the Prioritized List

HERC conducted the 13th biennial review of the Prioritized List of Health Services in 2015–17. Two major areas of focus during this biennial review included a review of the evidence for the treatment and prevention of obesity and a new process for the review of treatments with minimal or no clinical benefit, low cost-effectiveness or when potential harms outweigh benefits. Tables 1 through 4 show the structural changes made to lines during this biennial review to reflect changes in these areas as well as others, including the merging and other restructuring of lines, line movement and the creation of new lines.

**Table 1: Newly merged lines previously found on separate lines**

| 18-19 line | 18-19 line description  | 16-17 line     | 16-17 line description  |
|------------|---|----------------|---|
| 15         | Congenital infectious diseases/Medical therapy  | 15<br>16       | Congenital infectious diseases/Medical therapy<br>Congenital syphilis/Medical therapy   |
| 24         | Endocrine and metabolic disturbances specific to the fetus and newborn/Medical therapy    | 21<br>35<br>45 | Syndrome of “infant of a diabetic mother” and neonatal hypoglycemia/Medical therapy<br>Neonatal thyrotoxicosis/Medical therapy<br>Hypocalcemia, hypomagnesemia and other endocrine and metabolic disturbances specific to the fetus and newborn/Medical therapy |
| 359        | Deformity/closed dislocation of joint and recurrent joint dislocations/Surgical treatment | 364<br>392     | Deformity/closed dislocation of major joint and recurrent joint dislocations/Surgical treatment<br>Deformity/closed dislocation of minor joint and recurrent joint dislocations/Surgical treatment  |

**Table 2: Moved lines**

| 18-19 line | 18-19 line description                                | 16-17 line | 16-17 line description  |
|------------|---|------------|---|
| 43         | Neonatal infections other than sepsis/Medical therapy | 22         | Omphalitis of the newborn and neonatal infective mastitis/Medical therapy |

**Table 3: Restructured lines**

| 18-19 line | 18-19 line description  | 16-17 line | 16-17 line description  |
|------------|---|------------|---|
| 16         | Low birth weight; premature newborn/Medical therapy   | 17         | Very low birth weight (under 1500 grams)/Medical therapy  |
| 31         | Severe birth trauma for baby; intraventricular hemorrhage/Medical therapy   | 23         | Low birth weight (1500-2500 grams)/Medical therapy  |
|            |   | 34         | Severe birth trauma for baby/Medical therapy  |
| 27         | Type 2 diabetes mellitus/Medical therapy  | 30         | Type 2 diabetes mellitus/Medical therapy, bariatric surgery with BMI $\geq 35$  |
| 320        | Obesity in adults and children; overweight status in adults with cardiovascular risk factors/Behavioral interventions including intensive nutritional and physical activity counseling; bariatric surgery | 325        | Obesity (adult BMI $\geq 30$ , childhood BMI $\geq 95$ th percentile) and overweight in adults (BMI $\geq 25$ ) with cardiovascular risk factors/Intensive nutritional/ physical activity counseling and behavioral interventions   |
|            |   | 589        | Obesity (adult BMI $\geq 30$ , childhood BMI $\geq 95$ th percentile) and overweight in adults (BMI $\geq 25$ ) with cardiovascular risk factors/Non-intensive nutritional/ physical activity counseling and behavioral interventions; bariatric surgery for obesity with a significant comorbidity other than type 2 diabetes & BMI $\geq 35$ or BMI $\geq 40$ without a significant comorbidity |
| 78         | Injury to major blood vessels/Ligation, repair  | 82         | Injury to major blood vessels of extremities & neck/Ligation, repair  |
| 131        | Crush injuries other than digits; compartment syndrome/Medical and surgical treatment   | 135        | Crush injuries other than digits; compartment syndrome; injuries to blood vessel(s) of the neck/ Medical and surgical treatment   |
|            |   | 281        | Injury to blood vessels of the thoracic cavity/Repair   |

**Table 4: New lines**

| 18-19 line | 18-19 line description   |
|------------|--|
| 500        | Conditions for which certain treatments result in marginal clinical benefit or low cost-effectiveness/Medical and surgical treatment             |
| 660        | Conditions for which certain treatments have no clinically important benefit or have harms that outweigh benefits/Medical and surgical treatment |

# Review of the treatment and prevention of obesity

As of Jan. 1, 2008, the Prioritized List was modified to include a line in the funded region for covering intensive counseling on physical activity and behavioral modifications for treating obesity and overweight based on the recommendations of the U.S. Preventive Services Task Force. Additionally, a review of the evidence at that time led to bariatric surgery being included in the funded region for treating adults with both morbid obesity and type 2 diabetes mellitus. HERC created an Obesity Task Force in 2016 to help update a review of the evidence on treating and preventing obesity.

The Obesity Task Force reviewed the evidence on a variety of interventions including medications, behavioral interventions, devices and surgery. The task force also reviewed the evidence on environmental, policy and para-clinical interventions used to prevent and treat obesity. This is a part of a new endeavor by HERC to help coordinated care organizations (CCOs) identify evidence-based multisector interventions they can use to improve outcomes for individuals with significant chronic conditions. An evidence-based review on multisector interventions for tobacco cessation was also conducted during the past year, and others are planned for the coming biennium on preventing unintended pregnancy and early childhood caries.

As a result of the Obesity Task Force's work and the new HERC "Coverage Guidance on Metabolic and Bariatric Surgery":

- The lower obesity line was deleted as obsolete.
- Bariatric surgery was moved from the diabetes line to the funded obesity line. This will significantly expand coverage of surgical treatments, which are cost-effective for a broader population than was previously included in the bariatric surgery benefit.
- The guideline note addressing obesity and overweight was modified to clarify intensive behavioral interventions. Wording was added to clarify non-coverage of medications and devices for obesity.
- A new "Multisector Intervention Statement on the Prevention and Treatment of Obesity" was appended to the Prioritized List.
- Gastric banding was removed from coverage (adjustments and treatment of complication for existing devices will continue to be covered).
- Bariatric surgery must be performed exclusively at accredited programs.

- Coverage of bariatric surgery is expanded to adults with a BMI  $\geq 35$  with at least two serious obesity-related comorbidities (adults with type 2 diabetes already covered since 2008).
- Coverage of bariatric surgery is expanded to all adults with a BMI  $\geq 40$ .

See Appendix B for a full detailed account of the changes made to the Prioritized List resulting from this review of the treatment and prevention of obesity.

## Prioritization of services with low importance

Many treatments emerge that may be of high cost without necessarily offering any incremental benefit over existing treatments. Some treatments may not meet clinically important effectiveness criteria that would justify having a treatment be prioritized very high on the Prioritized List. HERC has thus made the following changes to better prioritize these services that have low importance:

- Create a new statement of intent to indicate criteria that could lead HERC to prioritize a service low on the Prioritized List.
- Create two new lines:
  - » A new line prioritized at line 500 titled **CONDITIONS FOR WHICH CERTAIN TREATMENTS RESULT IN MARGINAL CLINICAL BENEFIT OR LOW COST-EFFECTIVENESS.**
  - » A new line prioritized at the very end of the list titled **CONDITIONS FOR WHICH CERTAIN TREATMENTS HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS.**
- Create two new guideline notes associated with each of the new lines to list those condition-treatment pairings being included on each of the new lines, which will be particularly useful for those treatments that don't have procedure codes that normally appear on the Prioritized List.

Professional services of marginal benefit identified by a CPT or HCPCS code (such as surgeries and physician-administered drugs) can continue to be managed using pairings on existing low prioritized lines. If the diagnosis code does not otherwise appear on a line with the appropriate priority, the condition-treatment pair can now be added to one of these two new lines.

Ancillary (e.g., outpatient prescription drugs, durable medical equipment and supplies, adjunctive procedures) and diagnostic services (e.g., labs, imaging) can continue to be managed with ancillary and diagnostic guideline notes when limitations are intended. However, if evidence suggests their use imparts marginal or

no clinical benefit, is of low cost-effectiveness or has potential harms that outweigh benefits, ancillary and diagnostic services can be listed in one of the two new guideline notes associated with new, low-prioritized lines.

Because HERC is statutorily prohibited from conducting drug class evidence reviews or medical technology assessments solely of a prescription drug, HERC will rely on reports developed by Oregon's Pharmacy and Therapeutics Committee. These reviews will speak to the appropriate indications for the medications and describe their effects, including the magnitude of the effect. Based on the clinical importance of the effects/cost-effectiveness of the drugs in question, the HERC may include them in one of two new guidelines for services with low importance, if appropriate.

Please see Appendix B for a full detailed account of the changes made to the Prioritized List on the prioritization of services with low importance.

## Other biennial review changes

Some other noteworthy topics reviewed during this biennial review included:

1. Several lines with neonatal conditions were merged because conditions were very similar.
2. A merger of the tension headache and migraine headache lines was considered but rejected due to the considerable differences in efficacy of treatment between the diagnoses on these lines.
3. The minor joint injury line was deleted and the few unique diagnoses it contained were added to the major joint injury line.
4. Two lines containing large blood vessel injury diagnoses were merged, along with similar codes from a third line. The severity of the conditions and the effectiveness of treatment (if the patient could be stabilized) were similar.
5. Deletion of the only cancer line below the current funding line (SECONDARY AND ILL-DEFINED MALIGNANCIES) was considered but rejected due to the poor prognosis of many diagnoses on this line and/or the vagueness of the diagnoses, which did not allow evidence-based assessments of treatment effectiveness.
6. A higher prioritization of inguinal hernias that are not obstructed or gangrenous was considered but rejected due to a lack of evidence of harm if left untreated.

As this biennial review resulted in a net decrease of five lines, the new Prioritized List appearing in Appendix C is 660 lines long compared to the 665 lines in the 2016–17



list. Changes in line structure occurred both in the list's funded and non-funded regions, but the prioritization of the line above which the funding level was drawn for the 2016–17 list did not change. Therefore, line 469 on the new list equates to the funding level of the 2016–17 list at line 475.

# Interim modifications to the Prioritized List

In addition to the work on the biennial review of the Prioritized List, HERC continues to maintain the list as necessary during the interim periods. The 2018–19 Prioritized List incorporates interim modifications previously reported to legislative leadership in conjunction with the prioritized lists published on Oct. 1, 2015, Jan. 1, 2016, July 1, 2016, Oct. 1, 2016, and Jan. 1, 2017. These notices are located on HERC’s website. They include a detailed description of the thousands of changes due to incorporating new medical codes, advancements in technology, new data regarding existing technologies and error or omission corrections. HERC continues its use of a transparent process, which allows any stakeholder to request review of a prioritization topic.

# Recommendations

The Health Evidence Review Commission is pleased to offer these recommendations to the Governor and 79th Oregon Legislative Assembly:

1. Adopt the Prioritized List of Health Services for calendar years 2018–19 appearing in Appendix C. Once interim modifications to the list are completed in October 2017, the complete 2018–19 Prioritized List of Health Services will be posted on HERC’s web site.
2. Adopt the statements of intent and practice guidelines incorporated into the aforementioned Prioritized List.
3. Use the Prioritized List to delineate less important services to determine the benefit package under the Oregon Health Plan. A funding level covering lines 1-469 would equate to the level required under the terms and conditions of the 1115c waiver extension the Department of Health and Human Services granted in January 2017.

HERC thanks the Governor and Legislature for the opportunity to serve the citizens of Oregon.

# Appendix A: Commission and subcommittee membership

## Health Evidence Review Commission members

**Somnath Saha**, MD, MPH, Chair  
Physician, Portland

**Gerald Ahmann**, MD  
Physician, Salem (Resigned January 2016)

**Gary Allen**, DMD  
Dental Representative, Redmond (Joined January 2016)

**Wiley Chan**, MD  
Physician, Portland

**Irene Croswell**, RPh  
Pharmacy Representative, Tualatin

**Leda Garside**, RN, MBA  
Public Health Nurse, Lake Oswego

**Mark Gibson**  
Consumer Representative, Portland

**Holly Jo Hodges**, MD  
Insurance Industry Representative, Eugene

**Chris Labhart**  
Consumer Representative, John Day

**Kevin Olson**, MD  
Physician, Hospital Based, Portland (Joined February 2016)

**Vern Saboe**, DC  
Alternative & Complementary Medicine Provider, Albany (Term expired December 2015)

**Derrick Sorweide**, DO  
Physician, Osteopath, Keizer (Joined May 2015)

**Kim Tippens**, ND, MSAOM, MPH  
Alternative & Complementary Medicine Provider, Portland (Joined February 2016)

**Beth Kaplan Westbrook, PsyD**  
Behavioral Health Representative, Portland

**Susan Williams, MD**  
Physician, Roseburg

## Value-based Benefits Subcommittee members

**Kevin Olson, MD, Chair**  
Physician, Portland

**Susan Williams, MD, Vice Chair**  
Physician, Roseburg

**Gary Allen, DMD**  
Dentist, Redmond (Joined January 2016)

**Irene Croswell, RPh**  
Retail Pharmacist, Tualatin

**Mark Gibson**  
Consumer, Portland

**Holly Jo Hodges, MD**  
Medical Director, Eugene

**Laura Ocker, Lac**  
Acupuncturist, Milwaukee (Resigned December 2016)

**David Pollack, MD**  
Psychiatrist, West Linn

**Vern Saboe, DC**  
Chiropractor, Albany (Joined March 2016)

## HERC staff

**Darren Coffman**, Director

**Ariel Smits**, MD, MPH, Medical Director

**Cat Livingston**, MD, MPH, Associate Medical Director

**Jason Gingerich**, Policy Analyst

**Denise Taray**, RN, Policy Analyst

**Daphne Peck**, Communications Specialist

# Appendix B: Biennial review changes

## Changes related to the review of the treatment and prevention of obesity

Revised existing guideline notes as follows:

### **Guideline note 5, Obesity and overweight**

Line 325

Medical treatment of overweight (with known cardiovascular risk factors) and obesity in adults is limited to intensive counseling on nutrition and physical activity, provided by health care professionals. Intensive counseling is defined as face-to-face contact more than monthly. A multidisciplinary team is preferred, but a single clinician could also deliver intensive counseling in primary care or other settings.

Intensive counseling visits are included on this line for six months. Intensive counseling visits may continue for an additional 6 months (up to 12 months) as long as there is evidence of continued weight loss or improvement in cardiovascular risk factors based on the intervention. Maintenance visits at the conclusion of the intensive treatment are included on this line no more than monthly after this intensive counseling period. The characteristics of effective behavioral interventions include high intensity programs; multicomponent (including at a minimum diet and exercise), group-based commercial programs; Mediterranean diet; and the following sub-elements — calorie counting, contact with a dietician and comparison to peers.

Known cardiovascular risk factors in overweight persons for which this therapy is effective include hypertension, dyslipidemia, prediabetes or the metabolic syndrome.

Medical treatment of obesity in children is limited to comprehensive, intensive behavioral interventions. For treatment of children up to 12 years old, interventions may be targeted only to parents, or to both parents and children.

Pharmacological treatments and devices (e.g., gastric balloons, duodenal jejunal bypass liners and vagus nerve blocking devices) for obesity are not intended to be included as services on this line or any other line on the Prioritized List.

### **Guideline note 8, Bariatric surgery**

Line 325

Bariatric/metabolic surgery (limited to Roux-en-Y gastric bypass and sleeve gastrectomy) is included on Line 325 when the following criteria are met:

- A. Age  $\geq 18$
- B. The patient has obesity with a:
  - 1. BMI  $\geq 40$  OR
  - 2. BMI  $\geq 35$  with:
    - a. Type 2 diabetes, OR
    - b. At least two of the following other serious obesity-related comorbidities: hypertension, coronary heart disease, mechanical arthropathy in major weight bearing joint, sleep apnea
- C. Repeat bariatric surgery is included when it is a conversion from a less intensive (such as gastric band or sleeve gastrectomy) to a more intensive surgery (e.g., Roux-en-Y). Repair of surgical complications (excluding failure to lose sufficient weight) are also included on this and other lines. Reversal of surgical procedures and devices is included on this line when benefits of reversal outweigh harms.
- D. Participate in the following four evaluations and meet criteria as described.
  - 1. Psychosocial evaluation: (Conducted by a licensed mental health professional)
    - a. Evaluation to assess potential compliance with post-operative requirements.
    - b. Must remain free of abuse of or dependence on alcohol or marijuana during the six-month period immediately preceding surgery. No current use of nicotine or illicit drugs and must remain abstinent from their use during the six-month observation period. Testing will, at a minimum, be conducted within one month of the quit date and within one month of the surgery to confirm abstinence from illicit drugs. Tobacco abstinence will be confirmed in active smokers by negative cotinine levels at least six months apart, with the second test within one month of the surgery date.



- c. No mental or behavioral disorder that may interfere with postoperative outcomes<sup>1</sup>.
  - d. Patient with previous psychiatric illness must be stable for at least six months.
- 2. Medical evaluation: (Conducted by OHP primary care provider)
  - a. Pre-operative physical condition and mortality risk assessed with patient found to be an appropriate candidate.
  - b. Optimize medical control of diabetes, hypertension or other comorbid conditions.
  - c. Female patient not currently pregnant with no plans for pregnancy for at least 2 years post-surgery. Contraception methods reviewed with patient agreement to use effective contraception through 2nd year post-surgery.
- 3. Surgical evaluation: (Conducted by a licensed bariatric surgeon associated with program<sup>2</sup>)
  - a. Patient found to be an appropriate candidate for surgery at initial evaluation and throughout period leading to surgery.
  - b. Received counseling by a credentialed expert on the team regarding the risks and benefits of the procedure and understands the many potential complications of the surgery (including death) and the realistic expectations of post-surgical outcomes.
- 4. Dietician evaluation: (Conducted by licensed dietician)
  - a. Evaluation of adequacy of prior dietary efforts to lose weight. If no or inadequate prior dietary effort to lose weight, must undergo six-month clinically supervised weight reduction program (including intensive nutrition and physical activity counseling as defined by the USPSTF).
  - b. Counseling in dietary lifestyle changes.
- 5. Participate in additional evaluations:
  - a. Post-surgical attention to lifestyle, an exercise program and dietary changes and understands the need for post-surgical follow-up with all applicable professionals (e.g., nutritionist, psychologist/psychiatrist,

---

<sup>1</sup> Many patients (>50%) have depression as a comorbid diagnosis that, if treated, would not preclude their participation in the bariatric surgery program.

<sup>2</sup> All surgical services must be provided by a program with current accreditation (as a comprehensive center or low acuity center) by the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP).

exercise physiologist or physical therapist, support group participation, regularly scheduled physician follow-up visits).

Append a new multisector intervention statement to the Prioritized List as follows:

## **Multisector interventions: Prevention and treatment of obesity**

Limited evidence supports the following interventions:

### **School and child care settings**

- School-based interventions to reduce BMI (especially with physical activity focus)
- School nutrition policy and day care meal standards
- Family-based group education programs delivered in schools
- Obesity prevention interventions in child care settings (nutrition education, healthy cooking classes for 2–6 year-olds, physical activity and playful games)

### **Community level interventions**

- Environmental interventions (social marketing, cafeteria signs, farmers markets, walking groups, etc.)
- Introduction of light rail
- Community-based group health education and counseling interventions, workplace education interventions
- Workplace and college interventions to improve physical activity

### **Multiple settings**

- Interventions to reduce sedentary screen time (in some studies, also to increase physical activity and nutrition)
- Multicomponent individual mentored health promotion programs to prevent childhood obesity
- Parental support interventions for diet and physical activity (group education, mental health counseling)

### **Policy changes**

- Sugar sweetened beverage taxes
- Elimination of tax subsidy for advertising unhealthy food to children

This multisector interventions statement is based on the work of the HERC Obesity Task Force. The full summary of the evidence report is available at <http://www.oregon.gov/oha/herc/Pages/blog-obesityMSI.aspx>.

## Changes related to the prioritization of health services with low importance

Create a new statement of intent as follows:

### Statement of intent 3, Health services with low importance

It is the intent of HERC that therapies exhibiting one or more of the following characteristics generally be given low priority on the Prioritized List:

- Marginal clinical benefit
- No clinically important benefit
- Harms that outweigh benefits
- Very high cost in which the cost does not justify the benefit
- Significantly greater cost compared to alternate therapies when both have similar benefit
- Significant budget impact that could affect the overall Prioritized List funding level

Where possible, HERC prioritizes pairings of condition and treatment codes to reflect this lower priority, or simply does not pair a procedure code with one or more conditions if it exhibits one of these characteristics.

Codes for prescription drugs, durable medical equipment and supplies, certain adjunctive procedures and other ancillary services are not typically included on the Prioritized List. They are not always billed in conjunction with diagnosis codes, so it is more difficult to indicate the importance of these services through the prioritization process.

Based on evidence reviews by one of its subcommittees, the Pharmacy and Therapeutics Committee, or other reputable sources, HERC prioritizes such services regarded as having low importance when prescribed for certain conditions:

- On line 500, CONDITIONS FOR WHICH CERTAIN TREATMENTS RESULT IN MARGINAL CLINICAL BENEFIT OR LOW COST-EFFECTIVENESS, or

- Line 660, CONDITIONS FOR WHICH CERTAIN TREATMENTS HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS.

HERC lists the relevant condition/treatment pairings in Guideline Notes 168, TREATMENTS WITH MARGINAL CLINICAL BENEFIT OR LOW COST-EFFECTIVENESS FOR CERTAIN CONDITIONS, or 169, TREATMENTS THAT HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS FOR CERTAIN CONDITIONS.

Create two new lines as follows:

**Line 500**

Condition: Conditions for which certain treatments result in marginal clinical benefit or low cost-effectiveness

Treatment: Medical and surgical treatment

**Line 660**

Condition: Conditions for which certain treatments have no clinically important benefit or have harms that outweigh benefits

Treatment: Medical and surgical treatment

Create two new guideline notes as follows:

**Guideline note 168**, Treatments with marginal clinical benefit or low cost-effectiveness for certain conditions

The following treatments are prioritized on Line 500 for the conditions listed here:

| Condition                                    | Treatment |
|--|-----------|
| To be populated as the result of future work |           |
|  |           |
|  |           |

**Guideline note 169,** Treatments that have no clinically important benefit or have harms that outweigh benefits for certain conditions

The following treatments are prioritized on line 660, CONDITIONS FOR WHICH CERTAIN TREATMENTS HAVE NO CLINICALLY IMPORTANT BENEFIT OR HAVE HARMS THAT OUTWEIGH BENEFITS, for the conditions listed here:

| Condition                                    | Treatment |
|--|-----------|
| To be populated as the result of future work |           |
|  |           |
|  |           |

# Appendix C: Prioritized health services

## Frequently asked questions

### A user's guide to the Prioritized List

This summary of the most frequently asked questions and their answers should familiarize readers with the format of the Prioritized List, define important terms and provide educational examples.

1. **Does the line descriptor contain every diagnosis?** Each line has a description of both a condition and treatment. Some lines have only one condition, but others may have many. A line may include physical, behavioral health or oral health conditions. The line descriptor contains the most frequent condition or a cluster of conditions represented by the ICD-10-CM codes. For example, cystic fibrosis occurs by itself on line 20, but the codes on line 207 — described broadly as Zoonotic Bacterial Diseases — include plague, tularemia, anthrax, brucellosis, cat-scratch disease and other specific diseases.
2. **What do the line numbers represent?** The line numbers represent the rank order of the condition-treatment pairs assigned by the Health Evidence Review Commission. In terms of the benefit to the population being served, the services on line item 1 are most important to provide and those on line 660 are least important.
3. **How is the funding line established?** The 79th Oregon Legislative Assembly will review the Prioritized List included in this report. Per prior agreement with the Centers for Medicare and Medicaid Services (CMS), Oregon has agreed not to move the funding line from its current relative position for the duration of the current Medicaid waiver demonstration period. If this report is accepted, the Legislature is expected to establish the funding line for this list after line 469 as part of the state budget unless a waiver amendment to move the funding line is sought. Upon CMS approval, the benefit package represented by the services listed on or above the funding line established will be reimbursed under the Oregon Health Plan beginning no earlier than Jan. 1, 2018.

4. **Why do many diagnoses appear more than once?** A given diagnosis or condition may have a continuum of treatments including medical, surgical or transplantation. All transplantations for either bone marrow or solid organs have a separate line in addition to the medical/surgical treatment. These treatments of a condition may vary in their clinical effectiveness and/or cost-effectiveness and therefore the Health Evidence Review Commission gives them different rankings.
5. **What are statements of intent?** Statements of intent allow HERC to indicate its intent for coverage of services that cannot be easily identified by medical codes. The titles of these statements appear later in Appendix C immediately following the list of lines on the Prioritized List.
6. **What are practice guidelines?** Guidelines are used to further delineate conditions where the coding system does not adequately distinguish between subgroups that are treated differently or to indicate the most effective use of a particular treatment. This report provides a listing of the guideline titles. This includes guidelines associated with diagnostic and ancillary services that don't appear on the Prioritized List as well as services that do appear on the list. A full listing of the practice guidelines is posted on HERC's website.
7. **What about diagnostic services?** In most instances, diagnostic services are covered and do not appear on the list. Certain diagnostic services have either not been shown to be effective or do not affect management of the patient and the patient's health. If a condition is diagnosed that appears below the funding line, the diagnostic visit and any necessary tests will be covered; however, subsequent office visits and ancillary services such as home health services will not be covered.
8. **What about preventive services?** The Oregon Health Plan encourages prevention and early intervention. Effective preventive services for adults and children are ranked on line 3 and include services recommended by the U.S. Preventive Services Task Force ("A" and "B" Recommendations), American Academy of Pediatrics (Bright Futures Guidelines), Health Resources and Services Administration (Women's Preventive Services) and the Advisory Committee on Immunization Practices. In addition, preventive dental services are included on line 53.
9. **What are ancillary services and are they covered?** Ancillary services are those goods, services and therapies considered integral to the successful treatment of a condition. They include prescription drugs, durable medical equipment, hospital care and anesthesia. Ancillary services are generally reimbursable when used in conjunction with a covered condition, but may be subject to practice guidelines, Oregon Administrative Rules or other prior

authorization criteria. For some ancillary services, HERC has developed a guideline note to ensure appropriate utilization of these services. In addition, some ancillary services are listed in guideline notes 168 and 168 after HERC has found them to meet the criteria for these guideline notes, including little or no benefit, lack of cost-effectiveness or harms that outweigh benefits.

10. **What other resources are available to answer other questions?** See HERC's webpage for questions about the Prioritized List, the methodology used to create and maintain the list or other information concerning the work of the Health Evidence Review Commission.

See the Medical Assistance Programs webpage for questions about plan eligibility or administration, or contact our office at 503-373-1985.

## Line descriptions for the 2018–19 Prioritized List of Health Services

### Prioritized List of Health Services

Biennial list for planned implementation 1/1/2018–12/31/2019

| Line | Condition   | Treatment                               |
|------|---|---|
| 1    | Pregnancy   | Maternity care                          |
| 2    | Birth of infant   | Newborn care                            |
| 3    | Prevention services with evidence of effectiveness  | Medical therapy                         |
| 4    | Substance use disorder  | Medical/psychotherapy                   |
| 5    | Tobacco dependence  | Medical therapy/behavioral counseling   |
| 6    | Reproductive services   | Contraception management; sterilization |
| 7    | Major depression, recurrent; major depression, single episode, severe                           | Medical/psychotherapy                   |
| 8    | Type 1 diabetes mellitus  | Medical therapy                         |
| 9    | Asthma  | Medical therapy                         |
| 10   | Galactosemia  | Medical therapy                         |
| 11   | Respiratory conditions of fetus and newborn   | Medical therapy                         |
| 12   | HIV disease (including acquired immunodeficiency syndrome) and related opportunistic infections | Medical therapy                         |
| 13   | Congenital hypothyroidism   | Medical therapy                         |
| 14   | Phenylketonuria (PKU)   | Medical therapy                         |
| 15   | Congenital infectious diseases  | Medical therapy                         |
| 16   | Low birth weight; premature newborn   | Medical therapy                         |
| 17   | Neonatal myasthenia gravis  | Medical therapy                         |
| 18   | Feeding problems in newborns  | Medical therapy                         |
| 19   | Hydrocephalus and benign intracranial hypertension  | Medical and surgical treatment          |



|    |   |  |
|----|---|--|
| 20 | Cystic fibrosis   | Medical therapy                              |
| 21 | Vesicoureteral reflux   | Medical therapy, surgery                     |
| 22 | Schizophrenic disorders   | Medical/psychotherapy                        |
| 23 | Intracranial hemorrhages; cerebral convulsions, depression, coma, and other abnormal cerebral signs of the newborn            | Medical therapy                              |
| 24 | Endocrine and metabolic disturbances specific to the fetus and newborn  | Medical therapy                              |
| 25 | Dysplasia of cervix and cervical carcinoma in situ, cervical condyloma  | Medical and surgical treatment               |
| 26 | Bipolar disorders   | Medical/psychotherapy                        |
| 27 | Type 2 diabetes mellitus  | Medical therapy                              |
| 28 | Drug withdrawal syndrome in newborn   | Medical therapy                              |
| 29 | Regional enteritis, idiopathic proctocolitis, ulceration of intestine   | Medical and surgical treatment               |
| 30 | Epilepsy and febrile convulsions  | Medical therapy                              |
| 31 | Severe birth trauma for baby; intraventricular hemorrhage   | Medical therapy                              |
| 32 | Hematological disorders of fetus and newborn  | Medical therapy                              |
| 33 | Spina bifida  | Surgical treatment                           |
| 34 | Other congenital anomalies of musculoskeletal system  | Medical and surgical treatment               |
| 35 | Termination of pregnancy  | Induced abortion                             |
| 36 | Acquired hypothyroidism, dysmorphonogenic goiter  | Medical and surgical treatment               |
| 37 | Ectopic pregnancy; hydatidiform mole; choriocarcinoma   | Medical and surgical treatment               |
| 38 | Primary and secondary syphilis  | Medical therapy                              |
| 39 | Disorders relating to long gestation and high birthweight   | Medical therapy                              |
| 40 | Panhypopituitarism, iatrogenic and other pituitary disorders  | Medical therapy                              |
| 41 | Intussusception, volvulus, intestinal obstruction, hazardous foreign body in GI tract with risk of perforation or obstruction | Medical and surgical treatment               |
| 42 | Cleft palate with airway obstruction  | Medical and surgical treatment, orthodontics |
| 43 | Neonatal infections other than sepsis   | Medical therapy                              |
| 44 | Coarctation of the aorta  | Surgical treatment                           |
| 45 | Coronary artery anomaly   | Reimplantation of coronary artery            |
| 46 | Rheumatoid arthritis and other inflammatory polyarthropathies   | Medical therapy, injections                  |
| 47 | Deep abscesses, including appendicitis and periorbital abscess  | Medical and surgical treatment               |
| 48 | Chronic respiratory disease arising in the neonatal period  | Medical therapy                              |
| 49 | Congenital hydronephrosis   | Nephrectomy/repair                           |

|    |  |   |
|----|--|---|
| 50 | Pulmonary tuberculosis   | Medical therapy   |
| 51 | Acute pelvic inflammatory disease  | Medical and surgical treatment  |
| 52 | Gonococcal infections and other sexually transmitted diseases of the oral, anal and genitourinary tract                                  | Medical therapy   |
| 53 | Preventive dental services   | Cleaning, fluoride and sealants   |
| 54 | Dental conditions (eg. infection, pain, trauma)  | Emergency dental services   |
| 55 | Complicated stones of the gallbladder and bile ducts; cholecystitis  | Medical and surgical treatment  |
| 56 | Ulcers, gastritis, duodenitis, and GI hemorrhage   | Medical and surgical treatment  |
| 57 | Burn, full thickness greater than 10% of body surface  | Free skin graft, medical therapy  |
| 58 | Bronchiectasis   | Medical and surgical treatment  |
| 59 | End stage renal disease  | Medical therapy including dialysis  |
| 60 | Metabolic disorders  | Medical therapy   |
| 61 | Torsion of ovary   | Oophorectomy, ovarian cystectomy  |
| 62 | Substance-induced mood, anxiety, delusional and obsessive-compulsive disorders   | Medical/psychotherapy   |
| 63 | Spontaneous abortion; missed abortion  | Medical and surgical treatment  |
| 64 | Congenital anomalies of upper alimentary tract, excluding tongue   | Medical and surgical treatment  |
| 65 | Substance-induced delirium; substance intoxication and withdrawal  | Medical/psychotherapy   |
| 66 | Laryngeal stenosis or paralysis with airway complications  | Incision/excision/endoscopy   |
| 67 | Ventricular septal defect  | Closure   |
| 68 | Acute bacterial meningitis   | Medical therapy   |
| 69 | Acute and subacute ischemic heart disease, myocardial infarction   | Medical and surgical treatment  |
| 70 | Congenital pulmonary valve anomalies   | Pulmonary valve repair  |
| 71 | Neurological dysfunction in breathing, eating, swallowing, bowel, or bladder control caused by chronic conditions; attention to ostomies | Medical and surgical treatment (eg. G-tubes, J-tubes, respirators, tracheostomy, urological procedures) |
| 72 | Burn, partial thickness greater than 30% of body surface or with vital site; full thickness, less than 10% of body surface               | Free skin graft, medical therapy  |
| 73 | Polycythemia neonatorum, symptomatic   | Medical therapy   |
| 74 | Dermatomyositis, polymyositis  | Medical therapy   |
| 75 | Addison's disease  | Medical therapy   |
| 76 | Hypertension and hypertensive disease  | Medical therapy   |
| 77 | Patent ductus arteriosus; aortic pulmonary fistula/window  | Ligation  |
| 78 | Injury to major blood vessels  | Ligation/repair   |
| 79 | Phlebitis and thrombophlebitis, deep   | Medical therapy   |

|     |   |   |
|-----|---|---|
| 80  | Injury to internal organs   | Medical and surgical treatment  |
| 81  | Fracture of hip   | Medical and surgical treatment  |
| 82  | Myocarditis, pericarditis, and endocarditis   | Medical and surgical treatment  |
| 83  | Deep open wound of neck, including larynx; fracture of larynx or trachea  | Repair  |
| 84  | Diabetes mellitus with end stage renal disease  | Simultaneous pancreas/kidney (SPK) transplant, pancreas after kidney (PAK) transplant |
| 85  | Endocardial cushion defects   | Repair  |
| 86  | Congenital pulmonary valve atresia  | Shunt/repair  |
| 87  | Congenital anomalies of genitourinary system  | Reconstruction  |
| 88  | Necrotizing enterocolitis in fetus or newborn   | Medical and surgical treatment  |
| 89  | Discordant cardiovascular connections   | Repair  |
| 90  | Congenital mitral valve stenosis/insufficiency  | Mitral valve repair/replacement   |
| 91  | Guillain-Barre syndrome   | Medical therapy   |
| 92  | Severe/moderate head injury: hematoma/edema with persistent symptoms  | Medical and surgical treatment  |
| 93  | Childhood leukemias   | Medical therapy, which includes chemotherapy and Radiation therapy                    |
| 94  | Undescended testicle  | Surgical treatment  |
| 95  | Hereditary immune deficiencies  | Bone marrow transplant  |
| 96  | Diabetic and other retinopathy  | Medical, surgical, and laser treatment  |
| 97  | Borderline personality disorder   | Medical/psychotherapy   |
| 98  | Heart failure   | Medical therapy   |
| 99  | Cardiomyopathy  | Medical and surgical treatment  |
| 100 | End stage renal disease   | Renal transplant  |
| 101 | Congenital anomalies of digestive system and abdominal wall excluding necrosis; chronic intestinal pseudo-obstruction | Medical and surgical treatment  |
| 102 | Hemolytic disease due to isoimmunization, anemia due to transplacental hemorrhage, and fetal and neonatal jaundice    | Medical therapy   |
| 103 | Poisoning by ingestion, injection, and non-medicinal agents   | Medical therapy   |
| 104 | Botulism  | Medical therapy   |
| 105 | Tetralogy of Fallot (TOF); congenital venous abnormalities  | Repair  |
| 106 | Congenital stenosis and insufficiency of aortic valve   | Surgical valve replacement/valvuloplasty  |
| 107 | Giant cell arteritis, polymyalgia rheumatica and Kawasaki disease   | Medical therapy   |
| 108 | Fracture of ribs and sternum, open  | Medical and surgical treatment  |
| 109 | Subacute meningitis (eg. tuberculosis, cryptococcosis)  | Medical therapy   |
| 110 | Coagulation defects   | Medical therapy   |

|     |  |   |
|-----|--|---|
| 111 | Congenital heart block; other obstructive anomalies of heart   | Medical therapy   |
| 112 | Cancer of testis   | Medical and surgical treatment, which includes chemotherapy and radiation therapy |
| 113 | Cancer of eye and orbit  | Medical and surgical treatment, which includes chemotherapy and radiation therapy |
| 114 | Aplastic anemias; agranulocytosis  | Bone marrow transplant  |
| 115 | Chronic myeloid leukemia   | Medical therapy, which includes chemotherapy, radiation and radionuclide therapy  |
| 116 | Hodgkin's disease  | Bone marrow transplant  |
| 117 | Foreign body in pharynx, larynx, trachea, bronchus and esophagus   | Removal of foreign body   |
| 118 | Nutritional deficiencies   | Medical therapy   |
| 119 | Atrial septal defect, secundum   | Repair septal defect  |
| 120 | Choanal atresia  | Repair of choanal atresia   |
| 121 | Abuse and neglect  | Medical/psychotherapy   |
| 122 | Attention deficit/hyperactivity disorders  | Medical/psychotherapy   |
| 123 | Malaria, Chagas' disease and trypanosomiasis   | Medical therapy   |
| 124 | Anaphylactic shock; edema of larynx  | Medical therapy   |
| 125 | Thyrotoxicosis with or without goiter, endocrine exophthalmos; chronic thyroiditis   | Medical and surgical treatment which includes radiation therapy                   |
| 126 | Benign neoplasm of the brain and spinal cord   | Medical and surgical treatment, which includes chemotherapy and radiation therapy |
| 127 | Acute kidney injury  | Medical therapy including dialysis  |
| 128 | Common truncus   | Total repair/replant artery   |
| 129 | Granulomatosis with polyangiitis   | Medical therapy, which includes radiation therapy                                 |
| 130 | Total anomalous pulmonary venous connection  | Complete repair   |
| 131 | Crush injuries other than digits; compartment syndrome   | Medical and surgical treatment  |
| 132 | Open fracture/dislocation of extremities   | Medical and surgical treatment  |
| 133 | Cancer of cervix   | Medical and surgical treatment, which includes chemotherapy and radiation therapy |
| 134 | Interrupted aortic arch  | Transverse arch graft   |
| 135 | Hodgkin's disease  | Medical therapy, which includes chemotherapy and radiation therapy                |
| 136 | Traumatic amputation of leg(s) (complete)(partial) with and without complication   | Medical and surgical treatment  |
| 137 | Opportunistic infections in immunocompromised hosts; candidiasis of stoma; persons receiving continuous antibiotic therapy | Medical therapy   |
| 138 | Ebstein's anomaly  | Repair septal defect/valvuloplasty/replacement                                    |
| 139 | Glaucoma, other than primary angle-closure   | Medical, surgical and laser treatment   |
| 140 | Myasthenia gravis  | Medical therapy, thymectomy   |

|     |  |   |
|-----|--|---|
| 141 | Systemic lupus erythematosus, other diffuse diseases of connective tissue  | Medical therapy   |
| 142 | Conditions involving the temperature regulation of newborns  | Medical therapy   |
| 143 | Pneumothorax and pleural effusion tube thoracostomy  | Surgical therapy, medical therapy   |
| 144 | Hypothermia  | Medical therapy, extracorporeal circulation                                       |
| 145 | Anemia of prematurity or transient neonatal neutropenia  | Medical therapy   |
| 146 | Enteric infections and other bacterial food poisoning  | Medical therapy   |
| 147 | Glycogenosis   | Medical therapy   |
| 148 | Acquired hemolytic anemias   | Medical therapy   |
| 149 | Feeding and eating disorders of infancy or childhood   | Medical/psychotherapy   |
| 150 | Cervical vertebral dislocations/fractures, open or closed; other vertebral dislocations/fractures, open or unstable; spinal cord injuries with or without evidence of vertebral injury | Medical and surgical treatment  |
| 151 | Disorders of mineral metabolism, other than calcium  | Medical therapy   |
| 152 | Non-pulmonary tuberculosis   | Medical therapy   |
| 153 | Pyogenic arthritis   | Medical and surgical treatment  |
| 154 | Vascular insufficiency of intestine  | Surgical treatment  |
| 155 | Herpes zoster; herpes simplex and with neurological and ophthalmological complications   | Medical therapy   |
| 156 | Acromegaly and gigantism   | Medical therapy   |
| 157 | Cancer of colon, rectum, small intestine and anus  | Medical and surgical treatment, which includes chemotherapy and radiation therapy |
| 158 | Non-Hodgkin's lymphomas  | Medical therapy, which includes chemotherapy and radiation therapy                |
| 159 | Toxic epidermal necrolysis and staphylococcal scalded skin syndrome; Stevens-Johnson syndrome; erythema multiforme major; eczema herpeticum  | Medical therapy   |
| 160 | Traumatic amputation of arm(s), hand(s), thumb(s), and finger(s) (complete)(partial) with and without complication   | Medical and surgical treatment  |
| 161 | Granulocyte disorders  | Medical therapy   |
| 162 | Biliary atresia  | Liver transplant  |
| 163 | Non-Hodgkin's lymphomas  | Bone marrow transplant  |
| 164 | Carcinoma in situ of upper airway, including oral cavity   | Incision/excision, medical therapy  |
| 165 | Preventive foot care in high risk patients   | Medical and surgical treatment of toenails and hyperkeratoses of foot             |

|     |   |  |
|-----|---|--|
| 166 | Anal, rectal and colonic polyps   | Medical and surgical treatment   |
| 167 | Gonococcal and chlamydial infections of the eye; neonatal conjunctivitis                                | Medical therapy  |
| 168 | Complicated hernias; uncomplicated inguinal hernia in children age 18 and under; persistent hydrocele   | Repair   |
| 169 | Non-diabetic hypoglycemic coma  | Medical therapy  |
| 170 | Acute mastoiditis   | Mastoidectomy, medical therapy   |
| 171 | Amebiasis   | Medical therapy  |
| 172 | Hypertensive heart and renal disease  | Medical therapy  |
| 173 | Posttraumatic stress disorder   | Medical/psychotherapy  |
| 174 | Generalized convulsive or partial epilepsy without mention of impairment of consciousness               | Single focal surgery   |
| 175 | Polyarteritis nodosa and allied conditions  | Medical therapy  |
| 176 | Common ventricle  | Total repair   |
| 177 | Disorders of amino-acid transport and metabolism (non-PKU); hereditary fructose intolerance             | Medical therapy  |
| 178 | Intracerebral hemorrhage  | Medical therapy  |
| 179 | Acute leukemia, myelodysplastic syndrome  | Bone marrow transplant   |
| 180 | Ureteral stricture or obstruction; hydronephrosis; hydroureter  | Medical and surgical treatment   |
| 181 | Conditions involving exposure to natural elements (eg. lightning strike, heatstroke)                    | Medical therapy, burn treatment  |
| 182 | Septicemia  | Medical therapy  |
| 183 | Fracture of pelvis, open and closed   | Medical and surgical treatment   |
| 184 | Acute osteomyelitis   | Medical and surgical treatment   |
| 185 | Diverticulitis of colon   | Colon resection, medical therapy   |
| 186 | Rheumatic multiple valvular disease   | Surgical treatment   |
| 187 | Cushing's syndrome; hyperaldosteronism, other corticoadrenal overactivity, medulloadrenal hyperfunction | Medical therapy/adrenalectomy  |
| 188 | Congenital tricuspid atresia and stenosis   | Repair   |
| 189 | Chronic ischemic heart disease  | Medical and surgical treatment   |
| 190 | Neoplasms of islets of Langerhans   | Excision of tumor  |
| 191 | Cancer of breast; at high risk of breast cancer   | Medical and surgical treatment, which includes chemotherapy, radiation therapy and breast reconstruction |
| 192 | Hereditary angioedema   | Medical therapy  |
| 193 | Autism spectrum disorders   | Medical therapy/behavioral modification including applied behavior analysis                              |
| 194 | Hereditary anemias, hemoglobinopathies, and disorders of the spleen                                     | Medical therapy  |
| 195 | Acute pancreatitis  | Medical therapy  |

|     |   |   |
|-----|---|---|
| 196 | Subarachnoid and intracerebral hemorrhage/hematoma; cerebral aneurysm; compression of brain | Burr holes, craniectomy/craniotomy  |
| 197 | Burn, partial thickness without vital site requiring grafting, up to 30% of body surface    | Free skin graft, medical therapy  |
| 198 | Congenital lung anomalies   | Medical and surgical treatment  |
| 199 | Chronic hepatitis; viral hepatitis  | Medical therapy   |
| 200 | Cancer of soft tissue   | Medical and surgical treatment, which includes chemotherapy and radiation therapy |
| 201 | Cancer of bones   | Medical and surgical treatment, which includes chemotherapy and radiation therapy |
| 202 | Chronic organic mental disorders including dementias  | Consultation/medication management/behavioral support                             |
| 203 | Sleep apnea, narcolepsy and rem behavioral disorder   | Medical and surgical treatment  |
| 204 | Depression and other mood disorders, mild or moderate                                       | Medical/psychotherapy   |
| 205 | Pneumococcal pneumonia, other bacterial pneumonia, bronchopneumonia                         | Medical therapy   |
| 206 | Superficial abscesses and cellulitis  | Medical and surgical treatment  |
| 207 | Zoonotic bacterial diseases   | Medical therapy   |
| 208 | Deep open wound, with or without tendon or nerve involvement                                | Medical and surgical treatment  |
| 209 | Cancer of uterus  | Medical and surgical treatment, which includes chemotherapy and radiation therapy |
| 210 | Rupture of liver  | Suture/repair   |
| 211 | Cancer of thyroid   | Medical and surgical treatment, which includes chemotherapy and radiation therapy |
| 212 | Non-substance-related addictive behavioral disorders  | Medical/psychotherapy   |
| 213 | Bullous dermatoses of the skin  | Medical therapy   |
| 214 | Acute pulmonary heart disease and pulmonary emboli  | Medical and surgical treatment  |
| 215 | Cancer of kidney and other urinary organs   | Medical and surgical treatment, which includes chemotherapy and radiation therapy |
| 216 | Cancer of stomach   | Medical and surgical treatment, which includes chemotherapy and radiation therapy |
| 217 | Portal vein thrombosis  | Medical and surgical treatment  |
| 218 | Testicular cancer   | Bone marrow rescue and transplant   |
| 219 | Dental conditions (eg. periodontal disease)   | Basic periodontics  |
| 220 | Pulmonary fibrosis  | Medical and surgical treatment  |
| 221 | Dyslipidemias   | Medical therapy   |
| 222 | Disorders of fluid, electrolyte, and acid-base balance                                      | Medical therapy, dialysis   |
| 223 | Occupational lung diseases  | Medical therapy   |



|     |  |   |
|-----|--|---|
| 224 | Diseases and disorders of aortic valve   | Medical and surgical therapy  |
| 225 | Disorders of parathyroid gland; benign neoplasm of parathyroid gland; disorders of calcium metabolism                      | Medical and surgical treatment  |
| 226 | Acute inflammation of the heart due to rheumatic fever   | Medical therapy   |
| 227 | Ruptured viscus  | Repair  |
| 228 | Intestinal malabsorption   | Medical therapy   |
| 229 | Fracture of face bones; injury to optic and other cranial nerves   | Surgical treatment  |
| 230 | Malignant melanoma of skin   | Medical and surgical treatment, which includes chemotherapy and radiation therapy |
| 231 | Urinary fistula  | Surgical treatment  |
| 232 | Mycobacteria, fungal infections, toxoplasmosis, and other opportunistic infections   | Medical therapy   |
| 233 | Hypoplastic left heart syndrome  | Repair  |
| 234 | Adult respiratory distress syndrome; acute respiratory failure; respiratory conditions due to physical and chemical agents | Medical therapy   |
| 235 | Acute lymphocytic leukemias (adult) and multiple myeloma   | Medical therapy, which includes chemotherapy and radiation therapy                |
| 236 | Limb threatening vascular disease, infections, and vascular complications  | Medical and surgical treatment  |
| 237 | Tetanus  | Medical therapy   |
| 238 | Acute promyelocytic leukemia   | Medical therapy, which includes chemotherapy, radiation and radionuclide therapy  |
| 239 | Cancer of ovary  | Medical and surgical treatment, which includes chemotherapy and radiation therapy |
| 240 | Short bowel syndrome - age 5 or under  | Intestine and intestine/liver transplant  |
| 241 | Conditions requiring heart-lung and lung transplantation   | Heart-lung and lung transplant  |
| 242 | Acute and subacute necrosis of liver; specified inborn errors of metabolism (eg. maple syrup urine disease, tyrosinemia)   | Liver transplant  |
| 243 | Dermatological premalignant lesions and carcinoma in situ  | Destruct/excision/medical therapy   |
| 244 | Primary angle-closure glaucoma   | Medical, surgical and laser treatment   |
| 245 | Corneal ulcer; superficial injury of eye and adnexa  | Conjunctival flap; medical therapy  |
| 246 | Torsion of testis  | Orchiectomy, repair   |
| 247 | Life-threatening epistaxis   | Septoplasty/repair/control hemorrhage   |
| 248 | Retained intraocular foreign body, magnetic and nonmagnetic  | Foreign body removal  |
| 249 | Metabolic bone disease   | Medical therapy   |
| 250 | Parkinson's disease  | Medical therapy   |
| 251 | Chronic pancreatitis   | Medical therapy   |



|     |  |   |
|-----|--|---|
| 252 | Multiple sclerosis and other demyelinating diseases of central nervous system                          | Medical therapy   |
| 253 | Psychological factors aggravating physical condition (eg. asthma, chronic GI conditions, hypertension) | Medical/psychotherapy   |
| 254 | Arterial embolism/thrombosis: abdominal aorta, thoracic aorta  | Surgical treatment  |
| 255 | Chronic osteomyelitis  | Medical and surgical treatment  |
| 256 | Multiple endocrine neoplasia   | Medical and surgical treatment  |
| 257 | Deformities of head  | Craniotomy/craniectomy  |
| 258 | Diseases of mitral, tricuspid, and pulmonary valves  | Valvuloplasty, valve replacement, medical therapy                                 |
| 259 | Cancer of penis and other male genital organs  | Medical and surgical treatment, which includes chemotherapy and radiation therapy |
| 260 | Cancer of endocrine system, excluding thyroid; carcinoid syndrome                                      | Medical and surgical treatment, which includes chemotherapy and radiation therapy |
| 261 | Multiple myeloma   | Bone marrow transplant  |
| 262 | Cancer of retroperitoneum, peritoneum, omentum and mesentery   | Medical and surgical treatment, which includes chemotherapy and radiation therapy |
| 263 | Cancer of lung, bronchus, pleura, trachea, mediastinum and other respiratory organs                    | Medical and surgical treatment, which includes chemotherapy and radiation therapy |
| 264 | Congestive heart failure, cardiomyopathy, malignant arrhythmias, and complex congenital heart disease  | Cardiac transplant; heart/kidney transplant                                       |
| 265 | Trachoma   | Medical therapy   |
| 266 | Acute, subacute, chronic and other types of iridocyclitis  | Medical therapy   |
| 267 | Dental conditions (time sensitive events)  | Urgent dental services  |
| 268 | Rickettsial and other arthropod-borne diseases   | Medical therapy   |
| 269 | Diabetes insipidus   | Medical therapy   |
| 270 | Advanced degenerative disorders and conditions of globe  | Enucleation   |
| 271 | Cancer of bladder and ureter   | Medical and surgical treatment, which includes chemotherapy and radiation therapy |
| 272 | Traumatic amputation of foot/feet (complete) (partial) with and without complication                   | Medical and surgical treatment  |
| 273 | Leprosy, yaws, pinta   | Medical therapy   |
| 274 | Retinopathy of prematurity   | Cryosurgery   |
| 275 | Urologic infections  | Medical therapy   |
| 276 | Cancer of skin, excluding malignant melanoma   | Medical and surgical treatment, which includes chemotherapy and radiation therapy |
| 277 | Other psychotic disorders  | Medical/psychotherapy   |
| 278 | Hydrops fetalis  | Medical therapy   |
| 279 | Retinal detachment and other retinal disorders   | Retinal repair, vitrectomy  |
| 280 | Budd-Chiari syndrome, and other venous embolism and thrombosis   | Thrombectomy/ligation   |

|     |   |   |
|-----|---|---|
| 281 | Life-threatening cardiac arrhythmias  | Medical and surgical treatment  |
| 282 | Anorexia nervosa  | Medical/psychotherapy   |
| 283 | Chronic obstructive pulmonary disease; chronic respiratory failure  | Medical therapy   |
| 284 | Dissecting or ruptured aortic aneurysm  | Medical and surgical treatment  |
| 285 | Complications of a procedure always requiring treatment   | Medical and surgical treatment  |
| 286 | Cancer of vagina, vulva, and other female genital organs  | Medical and surgical treatment, which includes chemotherapy and radiation therapy                     |
| 287 | Cancer of oral cavity, pharynx, nose and larynx   | Medical and surgical treatment, which includes chemotherapy and radiation therapy                     |
| 288 | Osteopetrosis   | Bone marrow rescue and transplant   |
| 289 | Crush and other injuries of digits  | Medical and surgical treatment  |
| 290 | Acute stress disorder   | Medical/psychotherapy   |
| 291 | Adrenal or cutaneous hemorrhage of fetus or neonate   | Medical therapy   |
| 292 | Neurological dysfunction in posture and movement caused by chronic conditions   | Medical and surgical treatment (eg. durable medical equipment and orthopedic procedure)               |
| 293 | Anomalies of gallbladder, bile ducts, and liver   | Medical and surgical treatment  |
| 294 | Cancer of brain and nervous system  | Linear accelerator, medical and surgical treatment, which includes chemotherapy and radiation therapy |
| 295 | Aplastic anemias  | Medical therapy   |
| 296 | Cataract  | Extraction of cataract  |
| 297 | After cataract  | Discission, lens capsule  |
| 298 | Fistula involving female genital tract  | Closure of fistula  |
| 299 | Vitreous disorders  | Vitrectomy  |
| 300 | Cleft palate and/or cleft lip   | Excision and repair vestibule of mouth, orthodontics  |
| 301 | Gout  | Medical therapy   |
| 302 | Pertussis and diptheria   | Medical therapy   |
| 303 | Thrombocytopenia  | Medical and surgical treatment  |
| 304 | Viral pneumonia   | Medical therapy   |
| 305 | Disorders of arteries, other than carotid or coronary   | Medical and surgical treatment  |
| 306 | Paralytic ileus   | Medical and surgical treatment  |
| 307 | Cirrhosis of liver or biliary tract; Budd-Chiari syndrome; hepatic vein thrombosis; intrahepatic vascular malformations; Caroli's disease | Liver transplant, liver-kidney transplant   |
| 308 | Chronic inflammatory disorder of orbit  | Medical therapy   |
| 309 | Congenital dislocation of hip; coxa vara and valga  | Surgical treatment  |
| 310 | Corneal opacity and other disorders of cornea   | Keratoplasty  |
| 311 | Hearing loss - age 5 or under   | Medical therapy including hearing aids, limited surgical therapy                                      |
| 312 | Gender dysphoria/transsexualism   | Medical and surgical treatment/psychotherapy  |
| 313 | Disorders involving the immune system   | Medical therapy   |

|     |   |  |
|-----|---|--|
| 314 | Cancer of esophagus; Barrett's esophagus with dysplasia   | Medical and surgical treatment, which includes chemotherapy and radiation therapy                            |
| 315 | Cancer of liver   | Medical and surgical treatment, which includes chemotherapy and radiation therapy                            |
| 316 | Cancer of pancreas  | Medical and surgical treatment, which includes chemotherapy and radiation therapy                            |
| 317 | Stroke  | Medical therapy  |
| 318 | Purulent endophthalmitis  | Vitrectomy   |
| 319 | Foreign body in cornea and conjunctival sac   | Removal conjunctival foreign body  |
| 320 | Obesity in adults and children; overweight status in adults with cardiovascular risk factors                        | Behavioral interventions including intensive nutritional and physical activity counseling; bariatric surgery |
| 321 | Dermatologic hemangiomas, complicated   | Medical therapy  |
| 322 | Other aneurysm of peripheral artery   | Surgical treatment   |
| 323 | Sialoadenitis, abscess, fistula of salivary glands  | Medical and surgical treatment   |
| 324 | Cysticercosis, other cestode infection, trichinosis   | Medical therapy  |
| 325 | Non-dissecting aneurysm without rupture   | Surgical treatment   |
| 326 | Sensorineural hearing loss  | Cochlear implant   |
| 327 | Functional and mechanical disorders of the genitourinary system including bladder outlet obstruction                | Medical and surgical treatment   |
| 328 | Disseminated intravascular coagulation  | Medical and surgical treatment   |
| 329 | Cancer of prostate gland  | Medical and surgical treatment, which includes chemotherapy and radiation therapy                            |
| 330 | Systemic sclerosis; Sjogren's syndrome  | Medical therapy  |
| 331 | Acute promyelocytic leukemia  | Bone marrow transplant   |
| 332 | Conditions requiring hyperbaric oxygen therapy  | Hyperbaric oxygen  |
| 333 | Benign cerebral cysts   | Drainage   |
| 334 | Alcoholic fatty liver or alcoholic hepatitis, cirrhosis of liver  | Medical therapy  |
| 335 | Scleritis   | Medical therapy  |
| 336 | Rubeosis and other disorders of the iris  | Laser surgery  |
| 337 | Wound of eye globe  | Surgical repair  |
| 338 | Acute necrosis of liver   | Medical therapy  |
| 339 | Chronic kidney disease  | Medical therapy including dialysis   |
| 340 | Hereditary hemorrhagic telangiectasia   | Excision   |
| 341 | Rheumatic fever   | Medical therapy  |
| 342 | Other and unspecified anterior pituitary hyperfunction, benign neoplasm of thyroid gland and other endocrine glands | Medical and surgical treatment, which includes radiation therapy   |
| 343 | Dental conditions (eg. caries, fractured tooth)   | Basic restorative (e.g. composite restorations for anterior teeth, amalgam restorations for posterior teeth) |
| 344 | Dental conditions (eg. severe caries, infection)  | Oral surgery (i.e. extractions and other intraoral surgical procedures)                                      |

|     |   |  |
|-----|---|--|
| 345 | Neurological dysfunction in communication caused by chronic conditions  | Medical therapy  |
| 346 | Conditions of the back and spine with urgent surgical indications   | Surgical therapy   |
| 347 | Cardiac arrhythmias   | Medical therapy, pacemaker                                   |
| 348 | Mild/moderate birth trauma for baby   | Medical therapy  |
| 349 | Non-limb threatening peripheral vascular disease  | Surgical treatment   |
| 350 | Sarcoidosis   | Medical therapy  |
| 351 | Strabismus due to neurologic disorder   | Medical and surgical treatment                               |
| 352 | Urinary system calculus   | Medical and surgical treatment                               |
| 353 | Structural causes of amenorrhea   | Surgical treatment   |
| 354 | Penetrating wound of orbit  | Medical and surgical treatment                               |
| 355 | Closed fracture of extremities (except minor toes)  | Open or closed reduction                                     |
| 356 | Rheumatoid arthritis, osteoarthritis, osteochondritis dissecans, and aseptic necrosis of bone                                 | Arthroplasty/reconstruction                                  |
| 357 | Conditions of pulmonary artery  | Surgical treatment   |
| 358 | Body infestations (eg. lice, scabies)   | Medical therapy  |
| 359 | Deformity/closed dislocation of joint and recurrent joint dislocations  | Surgical treatment   |
| 360 | Chorioretinal inflammation  | Medical, surgical, and laser treatment                       |
| 361 | Scoliosis   | Medical and surgical therapy                                 |
| 362 | Dystonia (uncontrollable); laryngeal spasm  | Medical therapy  |
| 363 | Cyst and pseudocyst of pancreas   | Drainage of pancreatic cyst                                  |
| 364 | Acute sinusitis   | Medical and surgical treatment                               |
| 365 | Hyphema   | Removal of blood clot  |
| 366 | Allergic bronchopulmonary aspergillosis   | Medical therapy  |
| 367 | Entropion and trichiasis of eyelid  | Repair   |
| 368 | Streptococcal sore throat and scarlet fever; Vincent's disease; ulcer of tonsil; unilateral hypertrophy of tonsil             | Medical therapy, tonsillectomy/adenoidectomy                 |
| 369 | Intestinal parasites  | Medical therapy  |
| 370 | Amblyopia   | Medical and surgical treatment                               |
| 371 | Encephalocele   | Surgical treatment   |
| 372 | Benign neoplasm of respiratory and intrathoracic organs   | Lobectomy, medical therapy, which includes radiation therapy |
| 373 | Acne conglobata (severe cystic acne)  | Medical and surgical treatment                               |
| 374 | Retinal tear  | Laser prophylaxis  |
| 375 | Cholesteatoma; infections of the pinna  | Medical and surgical treatment                               |
| 376 | Disruptions of the ligaments and tendons of the arms and legs, excluding the knee, resulting in significant injury/impairment | Repair   |

|     |   |   |
|-----|---|---|
| 377 | Dysfunction resulting in loss of ability to maximize level of independence in self-directed care caused by chronic conditions that cause neurological dysfunction | Medical therapy (short term rehabilitation with defined goals)  |
| 378 | Esophageal stricture; achalasia   | Medical and surgical treatment  |
| 379 | Chronic ulcer of skin   | Medical and surgical treatment  |
| 380 | Esophagitis; GERD   | Short-term medical therapy; surgical treatment  |
| 381 | Bulimia nervosa and unspecified eating disorders  | Medical/psychotherapy   |
| 382 | Late syphilis   | Medical therapy   |
| 383 | Central serous chorioretinopathy  | Medical and surgical treatment  |
| 384 | Dental conditions (e.g. pulpal pathology, permanent anterior tooth)   | Basic endodontics (i.e. root canal therapy)   |
| 385 | Superficial injuries with infection   | Medical and surgical treatment  |
| 386 | Pituitary dwarfism  | Medical therapy   |
| 387 | Anogenital viral warts  | Medical and surgical treatment  |
| 388 | Separation anxiety disorder   | Medical/psychotherapy   |
| 389 | Acute otitis media  | Medical and surgical treatment  |
| 390 | Intestinal disaccharidase and other deficiencies  | Medical therapy   |
| 391 | Panic disorder; agoraphobia   | Medical/psychotherapy   |
| 392 | Croup syndrome, epiglottitis, acute laryngotracheitis   | Medical therapy, intubation, tracheotomy  |
| 393 | Strabismus without amblyopia and other disorders of binocular eye movements; congenital anomalies of eye; lacrimal duct obstruction in children                   | Medical and surgical treatment  |
| 394 | Anal fistula  | Sphincterotomy, fissurectomy, fistulectomy, medical therapy   |
| 395 | Endometriosis and adenomyosis   | Medical and surgical treatment  |
| 396 | Acute myeloid leukemia  | Bone marrow transplant and medical therapy, which includes chemotherapy, radiation and radionuclide therapy |
| 397 | Myeloid disorders   | Medical therapy, which includes chemotherapy and radiation therapy  |
| 398 | Influenza   | Medical therapy   |
| 399 | Chronic myeloid leukemia  | Bone marrow transplant  |
| 400 | Benign conditions of bone and joints at high risk for complications   | Medical and surgical treatment, which includes chemotherapy and radiation therapy                           |
| 401 | Conditions of the back and spine  | Risk assessment, physical modalities, cognitive behavioral therapy, medical therapy                         |
| 402 | Lymphadenitis   | Medical and surgical treatment  |
| 403 | Uterine leiomyoma and polyps  | Surgical treatment  |
| 404 | Aphakia and other disorders of lens   | Medical and surgical therapy  |
| 405 | Bilateral anomalies of external ear with impairment of hearing  | Reconstruct of ear canal  |
| 406 | Dissociative disorders  | Medical/psychotherapy   |

|     |  |  |
|-----|--|--|
| 407 | Epidermolysis bullosa  | Medical therapy  |
| 408 | Delirium due to medical causes   | Medical therapy  |
| 409 | Migraine headaches   | Medical therapy  |
| 410 | Dental conditions (eg. pulpal pathology, permanent bicuspid/premolar tooth)  | Basic endodontics (i.e. root canal therapy)  |
| 411 | Schizotypal personality disorders  | Medical/psychotherapy  |
| 412 | Balanoposthitis and other disorders of penis   | Medical and surgical treatment   |
| 413 | Overanxious disorder; generalized anxiety disorder; anxiety disorder, unspecified                                      | Medical/psychotherapy  |
| 414 | Transient cerebral ischemia; occlusion/stenosis of precerebral arteries without occlusion                              | Medical therapy; thromboendarterectomy   |
| 415 | Peripheral nerve entrapment; palmar fascial fibromatosis   | Medical and surgical treatment   |
| 416 | Meniere's disease  | Medical and surgical treatment   |
| 417 | Disorders of shoulder, including sprains/strains grade 4 through 6   | Repair/reconstruction, medical therapy   |
| 418 | Chronic leukemias with poor prognosis  | Medical therapy, which includes chemotherapy, radiation and radionuclide therapy             |
| 419 | Oppositional defiant disorder  | Medical/psychotherapy  |
| 420 | Menstrual bleeding disorders   | Medical and surgical treatment   |
| 421 | Lymphedema   | Medical therapy, other operation on lymph channel  |
| 422 | Complications of a procedure usually requiring treatment   | Medical and surgical treatment   |
| 423 | Adrenogenital disorders  | Medical and surgical treatment   |
| 424 | Severe inflammatory skin disease   | Medical therapy  |
| 425 | Acute peripheral motor and digital nerve injury  | Surgical therapy   |
| 426 | Non-malignant otitis externa   | Medical therapy  |
| 427 | Vaginitis and cervicitis   | Medical therapy  |
| 428 | Noninflammatory disorders and benign neoplasms of ovary, fallopian tubes and uterus; ovarian cysts; gonadal dysgenesis | Medical and surgical treatment   |
| 429 | Urethral fistula   | Excision, medical therapy  |
| 430 | Internal derangement of knee and ligamentous disruptions of the knee, resulting in significant injury/impairment       | Repair, medical therapy  |
| 431 | Persistent depressive disorder   | Medical/psychotherapy  |
| 432 | Hypospadias and epispadias   | Repair   |
| 433 | Cancer of gallbladder and other biliary  | Medical and surgical treatment, which includes chemotherapy and radiation therapy            |
| 434 | Precancerous vulvar conditions   | Medical therapy  |
| 435 | Recurrent erosion of the cornea  | Anterior stromal puncture, removal of corneal epithelium; with or without chemocauterization |
| 436 | Stereotypy/habit disorder and self-abusive behavior due to neurological dysfunction                                    | Consultation/medication management/limited behavioral modification                           |

|     |  |   |
|-----|--|---|
| 437 | Foreign body in uterus, vulva and vagina                                     | Medical and surgical treatment  |
| 438 | Residual foreign body in soft tissue   | Removal   |
| 439 | Venous tributary (branch) occlusion; central retinal vein occlusion          | Surgical treatment including laser surgery, medical therapy including injection     |
| 440 | Trigeminal and other nerve disorders   | Medical and surgical treatment, which includes radiation therapy                    |
| 441 | Malunion and nonunion of fracture  | Surgical treatment  |
| 442 | Dental conditions (eg. pulpal pathology, permanent molar tooth)              | Basic endodontics (i.e. root canal therapy)   |
| 443 | Adjustment disorders   | Medical/psychotherapy   |
| 444 | Hearing loss - over age of five  | Medical therapy including hearing aids, limited surgical therapy                    |
| 445 | Tourette's disorder and tic disorders  | Medical/psychotherapy   |
| 446 | Atherosclerosis, aortic and renal  | Medical and surgical treatment  |
| 447 | Degeneration of macula and posterior pole                                    | Medical, surgical and laser treatment   |
| 448 | Reactive attachment disorder of infancy or early childhood                   | Medical/psychotherapy   |
| 449 | Disorders of refraction and accommodation                                    | Medical therapy   |
| 450 | Exophthalmos and cysts of the eye and orbit                                  | Surgical treatment  |
| 451 | Dental conditions (eg. missing teeth, prosthesis failure)                    | Removable prosthodontics (e.g. full and partial dentures, relines)                  |
| 452 | Rectal prolapse  | Surgical treatment  |
| 453 | Urinary incontinence   | Medical and surgical treatment  |
| 454 | Disorders of plasma protein metabolism                                       | Medical therapy   |
| 455 | Dental conditions (e.g. pulpal pathology, permanent anterior tooth)          | Advanced endodontics (e.g. retreatment of previous root canal therapy)              |
| 456 | Simple phobias and social anxiety disorder                                   | Medical/psychotherapy   |
| 457 | Acute bronchitis and bronchiolitis   | Medical therapy   |
| 458 | Central pterygium affecting vision   | Excision or transposition of pterygium without graft, radiation therapy             |
| 459 | Branchial cleft cyst; thyroglossal duct cyst; cyst of pharynx or nasopharynx | Excision, medical therapy   |
| 460 | Obsessive-compulsive disorders   | Medical/psychotherapy   |
| 461 | Osteoarthritis and allied disorders  | Medical therapy, injections   |
| 462 | Atelectasis (collapse of lung)   | Medical therapy   |
| 463 | Chronic sinusitis  | Medical and surgical treatment  |
| 464 | Uterine prolapse; cystocele  | Medical and surgical treatment  |
| 465 | Brachial plexus lesions  | Medical therapy   |
| 466 | Dental conditions (eg. caries, fractured tooth)                              | Advanced restorative (i.e. basic crowns)  |
| 467 | Gonadal dysfunction, menopausal management                                   | Oophorectomy, orchiectomy, hormonal replacement for purposes other than infertility |
| 468 | Encopresis not due to a physiological condition                              | Medical/psychotherapy   |



|   |  |  |
|---|--|--|
| 469   | Acquired ptosis and other eyelid disorders with vision impairment  | Ptosis repair  |
| <b>Equivalent to the funding level for the 2016-2017 Prioritized List</b> |  |  |
| 470   | Keratoconjunctivitis   | Medical and surgical treatment                                 |
| 471   | Selective mutism   | Medical/psychotherapy  |
| 472   | Thrombosed and complicated hemorrhoids   | Hemorrhoidectomy, incision                                     |
| 473   | Chronic otitis media; open wound of ear drum   | PE tubes/adenoidectomy/tympanoplasty, medical therapy          |
| 474   | Otosclerosis   | Medical and surgical treatment                                 |
| 475   | Foreign body in ear and nose   | Removal of foreign body  |
| 476   | Closed dislocations/fractures of non-cervical vertebral column without neurologic injury or structural instability | Medical and surgical treatment                                 |
| 477   | Conduct disorder, age 18 or under  | Medical/psychotherapy  |
| 478   | Breast cysts and other disorders of the breast   | Medical and surgical treatment                                 |
| 479   | Cysts of Bartholin's gland and vulva   | Incision and drainage, medical therapy                         |
| 480   | Lichen planus  | Medical therapy  |
| 481   | Rupture of synovium  | Removal of Baker's cyst  |
| 482   | Enophthalmos   | Orbital implant  |
| 483   | Bell's palsy, exposure keratoconjunctivitis  | Tarsorrhaphy   |
| 484   | Peripheral enthesopathies  | Medical therapy  |
| 485   | Angioedema   | Medical therapy  |
| 486   | Closed fracture of one or more phalanges of the foot, not including the great toe                                  | Medical and surgical treatment                                 |
| 487   | Dermatophytosis of nail, groin, and foot and other dermatomycosis  | Medical and surgical treatment                                 |
| 488   | Closed fractures of ribs, sternum and coccyx   | Medical therapy  |
| 489   | Spastic diplegia   | Rhizotomy  |
| 490   | Dental conditions (eg. periodontal disease)  | Advanced periodontics (e.g. surgical procedures and splinting) |
| 491   | Hepatorenal syndrome   | Medical therapy  |
| 492   | Paraphilias and other psychosexual disorders   | Medical/psychotherapy  |
| 493   | Ectropion and benign neoplasm of eye   | Ectropion repair   |
| 494   | Raynaud's syndrome   | Medical therapy  |
| 495   | Calcium pyrophosphate deposition disease (CPPD) and hydroxyapatite deposition disease                              | Medical therapy  |
| 496   | Phimosis   | Surgical treatment   |
| 497   | Cerumen impaction  | Removal of ear wax   |
| 498   | Sialolithiasis, mucocele, disturbance of salivary secretion, other and unspecified diseases of salivary glands     | Medical and surgical treatment                                 |
| 499   | Chronic conjunctivitis, blepharoconjunctivitis   | Medical therapy  |
| 500   | Conditions for which certain treatments result in marginal clinical benefit or low cost-effectiveness              | Medical and surgical treatment                                 |



|     |   |  |
|-----|---|--|
| 501 | Other disorders of synovium, tendon and bursa, costochondritis, and chondrodystrophy                                      | Medical therapy  |
| 502 | Erythematous conditions   | Medical therapy  |
| 503 | Peripheral enthesopathies   | Surgical treatment   |
| 504 | Nasal polyps, other disorders of nasal cavity and sinuses   | Medical and surgical treatment   |
| 505 | Dental conditions (e.g. pulpal pathology, permanent bicuspid/premolar tooth)  | Advanced endodontics (e.g. retreatment of previous root canal therapy) |
| 506 | Circumscribed scleroderma   | Medical therapy  |
| 507 | Peripheral nerve disorders  | Medical therapy  |
| 508 | Dysfunction of nasolacrimal system in adults; lacrimal system laceration  | Medical and surgical treatment   |
| 509 | Benign neoplasm of kidney and other urinary organs  | Medical and surgical treatment   |
| 510 | Vertiginous syndromes and other disorders of vestibular system  | Medical and surgical treatment   |
| 511 | Esophagitis and GERD; esophageal spasm; asymptomatic diaphragmatic hernia   | Medical therapy  |
| 512 | Hidradenitis suppurativa; dissecting cellulitis of the scalp  | Medical therapy  |
| 513 | Chronic prostatitis, other disorders of prostate  | Medical therapy  |
| 514 | Phlebitis and thrombophlebitis, superficial   | Medical therapy  |
| 515 | Disorders of sweat glands   | Medical therapy  |
| 516 | Paralysis of vocal cords or larynx  | Incision/excision/endoscopy  |
| 517 | Postthrombotic syndrome   | Medical therapy  |
| 518 | Foreign body in gastrointestinal tract without risk of perforation or obstruction   | Medical therapy  |
| 519 | Panniculitis  | Medical therapy  |
| 520 | Rosacea; acne   | Medical and surgical treatment   |
| 521 | Sexual dysfunction  | Psychotherapy, medical and surgical treatment                          |
| 522 | Uncomplicated hernia and ventral hernia (other than inguinal hernia in children age 18 and under or diaphragmatic hernia) | Repair   |
| 523 | Benign neoplasm of nasal cavities, middle ear and accessory sinuses   | Excision, reconstruction   |
| 524 | Chronic anal fissure  | Sphincterotomy, fissurectomy, fistulectomy, medical therapy            |
| 525 | Deformities of upper body and all limbs   | Repair/revision/reconstruction/relocation/medical therapy              |
| 526 | Disorders of function of stomach and other functional digestive disorders   | Medical and surgical therapy   |
| 527 | Conditions of the back and spine without urgent surgical indications  | Surgical therapy   |
| 528 | Fibromyalgia, chronic fatigue syndrome, and related disorders   | Medical therapy  |

|     |   |   |
|-----|---|---|
| 529 | Chronic pelvic inflammatory disease, pelvic pain syndrome, dyspareunia  | Medical and surgical treatment  |
| 530 | Atopic dermatitis   | Medical therapy   |
| 531 | Contact dermatitis and other eczema   | Medical therapy   |
| 532 | Hypotension   | Medical therapy   |
| 533 | Viral, self-limiting encephalitis, myelitis and encephalomyelitis   | Medical therapy   |
| 534 | Peripheral nerve disorders  | Surgical treatment  |
| 535 | Dental conditions (e.g. pulpal pathology, permanent molar tooth)  | Advanced endodontics (e.g. retreatment of previous root canal therapy)            |
| 536 | Ichthyosis  | Medical therapy   |
| 537 | Lesion of plantar nerve; plantar fascial fibromatosis   | Medical therapy, excision   |
| 538 | Tension headaches   | Medical therapy   |
| 539 | Mild psoriasis; dermatophytosis: scalp, hand, body, deep-seated   | Medical therapy   |
| 540 | Deformities of foot   | Fasciotomy/incision/repair/arthrodesis  |
| 541 | Foreign body granuloma of muscle, skin and subcutaneous tissue  | Removal of granuloma  |
| 542 | Hydrocele   | Medical therapy, excision   |
| 543 | Symptomatic urticaria   | Medical therapy   |
| 544 | Impulse disorders   | Medical/psychotherapy   |
| 545 | Sublingual, scrotal, and pelvic varices   | Venous injection, vascular surgery  |
| 546 | Aseptic meningitis  | Medical therapy   |
| 547 | TMJ disorder  | TMJ splints   |
| 548 | Chronic disease of tonsils and adenoids   | Tonsillectomy and adenoidectomy   |
| 549 | Somatic symptoms and related disorders  | Consultation  |
| 550 | Other noninfectious gastroenteritis and colitis   | Medical therapy   |
| 551 | Hematoma of auricle or pinna and hematoma of external ear   | Drainage  |
| 552 | Mild eczematous and other hypertrophic or atrophic conditions of skin   | Medical therapy   |
| 553 | Chondromalacia  | Medical therapy   |
| 554 | Cyst of kidney, acquired  | Medical therapy   |
| 555 | Dysmenorrhea  | Medical and surgical treatment  |
| 556 | Benign neoplasm of bone and articular cartilage including osteoid osteomas; benign neoplasm of connective and other soft tissue | Medical and surgical treatment, which includes chemotherapy and radiation therapy |
| 557 | Spastic dysphonia   | Medical therapy   |
| 558 | Macromastia   | Breast reduction  |
| 559 | Allergic rhinitis and conjunctivitis, chronic rhinitis  | Medical therapy   |
| 560 | Cancer of liver and intrahepatic bile ducts   | Liver transplant  |
| 561 | Benign neoplasm and conditions of external female genital organs  | Excision  |

|     |  |   |
|-----|--|---|
| 562 | Hordeolum and other deep inflammation of eyelid; chalazion                                   | Incision and drainage, medical therapy  |
| 563 | Acute anal fissure   | Fissurectomy, medical therapy   |
| 564 | Pleurisy   | Medical therapy   |
| 565 | Peritoneal adhesion  | Surgical treatment  |
| 566 | Dermatitis due to substances taken internally  | Medical therapy   |
| 567 | Blepharitis  | Medical therapy   |
| 568 | Unspecified urinary obstruction and benign prostatic hyperplasia without obstruction         | Medical therapy   |
| 569 | Other complications of a procedure   | Medical and surgical treatment  |
| 570 | Anemias due to disease   | Medical therapy   |
| 571 | Personality disorders excluding borderline and schizotypal                                   | Medical/psychotherapy   |
| 572 | Acute non-suppurative labyrinthitis  | Medical therapy   |
| 573 | Deviated nasal septum, acquired deformity of nose, other diseases of upper respiratory tract | Excision of cyst/rhinectomy/prosthesis  |
| 574 | Stomatitis and other diseases of oral soft tissues   | Incision and drainage, medical therapy  |
| 575 | Cavus deformity of foot; flat foot; polydactyly and syndactyly of toes                       | Medical therapy, orthotic   |
| 576 | Infectious mononucleosis   | Medical therapy   |
| 577 | Urethritis, non-sexually transmitted   | Medical therapy   |
| 578 | Congenital anomalies of female genital organs excluding vagina                               | Surgical treatment  |
| 579 | Thrombotic disorders   | Medical therapy   |
| 580 | Candidiasis of mouth, skin and nails   | Medical therapy   |
| 581 | Benign neoplasm of male genital organs: testis, prostate, epididymis                         | Medical and surgical treatment  |
| 582 | Atrophy of edentulous alveolar ridge   | Vestibuloplasty, grafts, implants   |
| 583 | Disease of nails, hair and hair follicles  | Medical therapy   |
| 584 | Acute tonsillitis other than beta-streptococcal  | Medical therapy   |
| 585 | Corns and calluses   | Medical therapy   |
| 586 | Synovitis and tenosynovitis  | Medical therapy   |
| 587 | Prolapsed urethral mucosa  | Surgical treatment  |
| 588 | Dental conditions (eg. caries, fractured tooth)  | Advanced restorative-elective (inlays, onlays, gold foil and high noble metal restorations) |
| 589 | Secondary and ill-defined malignant neoplasms  | Medical and surgical treatment  |
| 590 | Ganglion   | Excision  |
| 591 | Episcleritis   | Medical therapy   |
| 592 | Diaper rash  | Medical therapy   |
| 593 | Tongue tie and other anomalies of tongue   | Frenotomy, tongue tie   |
| 594 | Inconsequential cysts of oral soft tissues   | Incision and drainage   |
| 595 | Congenital deformities of knee   | Medical and surgical treatment  |
| 596 | Chronic pancreatitis   | Surgical treatment  |

|     |  |  |
|-----|--|--|
| 597 | Herpes simplex without complications, excluding genital herpes   | Medical therapy  |
| 598 | Dental conditions (eg. missing teeth)  | Complex prosthodontics (i.e. fixed bridges, overdentures)                            |
| 599 | Congenital anomalies of the ear without impairment of hearing; unilateral anomalies of the ear                                       | Otoplasty, repair and amputation   |
| 600 | Keloid scar; other abnormal granulation tissue   | Intralesional injections/destruction/excision, radiation therapy                     |
| 601 | Disorders of soft tissue   | Medical therapy  |
| 602 | Minor burns  | Medical therapy  |
| 603 | Disorders of sleep without sleep apnea   | Medical therapy  |
| 604 | Oral aphthae   | Medical therapy  |
| 605 | Sprains and strains of adjacent muscles and joints, minor  | Medical therapy  |
| 606 | Asymptomatic urticaria   | Medical therapy  |
| 607 | Fingertip avulsion   | Repair without pedicle graft   |
| 608 | Abuse of nonaddictive substances   | Medical therapy  |
| 609 | Minor head injury: hematoma/edema with no persistent symptoms  | Medical therapy  |
| 610 | Viral warts excluding venereal warts   | Medical and surgical treatment, cryosurgery  |
| 611 | Acute upper respiratory infections and common cold   | Medical therapy  |
| 612 | Other viral infections   | Medical therapy  |
| 613 | Pharyngitis and laryngitis and other diseases of vocal cords   | Medical therapy  |
| 614 | Anomalies of relationship of jaw to cranial base, major anomalies of jaw size, other specified and unspecified dentofacial anomalies | Osteoplasty, maxilla/mandible  |
| 615 | Dental conditions (eg. malocclusion)   | Orthodontia (i.e. fixed and removable appliances and associated surgical procedures) |
| 616 | Dental conditions (eg. missing teeth)  | Implants (i.e. implant placement and associated crown or prosthesis)                 |
| 617 | Benign lesions of tongue   | Excision   |
| 618 | Uncomplicated hemorrhoids  | Hemorrhoidectomy, medical therapy  |
| 619 | Prevention services with limited or no evidence of effectiveness   | Medical therapy  |
| 620 | Open wound of internal structures of mouth without complication  | Repair soft tissues  |
| 621 | Sebaceous cyst   | Medical and surgical treatment   |
| 622 | Seborrheic keratosis, dyschromia, and vascular disorders, scar conditions, and fibrosis of skin                                      | Medical and surgical treatment   |
| 623 | Redundant prepuce  | Elective circumcision  |
| 624 | Conjunctival cyst  | Excision of conjunctival cyst  |
| 625 | Benign neoplasms of skin and other soft tissues  | Medical therapy  |
| 626 | Disease of capillaries   | Excision   |

|     |  |  |
|-----|--|--|
| 627 | Benign cervical conditions   | Medical therapy                          |
| 628 | Cyst, hemorrhage, and infarction of thyroid  | Surgical treatment                       |
| 629 | Pica   | Medical/psychotherapy                    |
| 630 | Acute viral conjunctivitis   | Medical therapy                          |
| 631 | Muscular calcification and ossification  | Medical therapy                          |
| 632 | Superficial wounds without infection and contusions  | Medical therapy                          |
| 633 | Chronic bronchitis   | Medical therapy                          |
| 634 | Galactorrhea, mastodynia, atrophy, benign neoplasms and unspecified disorders of the breast            | Medical and surgical treatment           |
| 635 | Benign polyps of vocal cords   | Medical therapy, stripping               |
| 636 | Benign neoplasms of digestive system   | Surgical treatment                       |
| 637 | Varicose veins of lower extremities without ulcer or other major complication                          | Stripping/sclerotherapy, medical therapy |
| 638 | Hypertelorism of orbit   | Orbitotomy                               |
| 639 | Gallstones without cholecystitis; biliary colic  | Medical therapy, cholecystectomy         |
| 640 | Gynecomastia   | Mastectomy                               |
| 641 | TMJ disorders  | TMJ surgery                              |
| 642 | Edema and other conditions involving the skin of the fetus and newborn                                 | Medical therapy                          |
| 643 | Dental conditions where treatment is chosen primarily for aesthetic considerations                     | Cosmetic dental services                 |
| 644 | Dental conditions where treatment results in marginal improvement                                      | Elective dental services                 |
| 645 | Agenesis of lung   | Medical therapy                          |
| 646 | Central retinal artery occlusion   | Paracentesis of aqueous                  |
| 647 | Mental disorders with no or minimally effective treatments or no treatment necessary                   | Evaluation                               |
| 648 | Intracranial conditions with no or minimally effective treatments or no treatment necessary            | Evaluation                               |
| 649 | Infectious diseases with no or minimally effective treatments or no treatment necessary                | Evaluation                               |
| 650 | Endocrine and metabolic conditions with no or minimally effective treatments or no treatment necessary | Evaluation                               |
| 651 | Cardiovascular conditions with no or minimally effective treatments or no treatment necessary          | Evaluation                               |
| 652 | Sensory organ conditions with no or minimally effective treatments or no treatment necessary           | Evaluation                               |
| 653 | Neurologic conditions with no or minimally effective treatments or no treatment necessary              | Evaluation                               |
| 654 | Dermatological conditions with no or minimally effective treatments or no treatment necessary          | Evaluation                               |
| 655 | Respiratory conditions with no or minimally effective treatments or no treatment necessary             | Evaluation                               |

|     |   |                                 |
|-----|---|---------------------------------|
| 656 | Genitourinary conditions with no or minimally effective treatments or no treatment necessary                      | Evaluation                      |
| 657 | Musculoskeletal conditions with no or minimally effective treatments or no treatment necessary                    | Evaluation                      |
| 658 | Gastrointestinal conditions with no or minimally effective treatments or no treatment necessary                   | Evaluation                      |
| 659 | Miscellaneous conditions with no or minimally effective treatments or no treatment necessary                      | Evaluation                      |
| 660 | Conditions for which certain treatments have no clinically important benefit or have harms that outweigh benefits | Medical and surgical treatments |

## Statements of intent and guideline descriptions for the 2018–19 Prioritized List of Health Services

### Statements of intent

Statement of intent 1: Palliative care

Statement of intent 2: Death with Dignity Act

Statement of intent 3: Health services with low importance

### Guideline notes for ancillary and diagnostic services not appearing on the Prioritized List

- Guideline note A1: Nerve blocks
- Guideline note A2: Self-monitoring of blood glucose in diabetes
- Guideline note A3: IVC filters for trauma
- Guideline note A4: Smoking cessation and elective surgical procedures
- Guideline note D1: Non-prenatal genetic testing guideline
- Guideline note D2: Implantable cardiac loop recorders
- Guideline note D3: Echocardiograms with contrast for cardiac conditions other than cardiac anomalies
- Guideline note D4: Advanced imaging for low back pain
- Guideline note D5: Neuroimaging for headache
- Guideline note D6: MRI for breast cancer screening
- Guideline note D7: Neuroimaging in dementia
- Guideline note D8: Diagnostic testing for obstructive sleep apnea (OSA) in adults
- Guideline note D9: MRI for breast cancer diagnosis
- Guideline note D10: MRI in multiple sclerosis
- Guideline note D11: MRI of the spine (cervical and thoracic)

|                     |  |
|---------------------|--|
| Guideline note D12: | Upper endoscopy for GERD or dyspepsia symptoms                 |
| Guideline note D13: | Screening for carotid artery stenosis                          |
| Guideline note D14: | Lung cancer screening  |
| Guideline note D15: | Computer-aided mammography                                     |
| Guideline note D16: | Osteoporosis screening and monitoring in adults                |
| Guideline note D17: | Prenatal genetic testing                                       |
| Guideline note D18: | Advanced imaging for staging of prostate cancer                |
| Guideline note D19: | SPECT  |
| Guideline note D20: | Ophthalmology diagnostic visits                                |
| Guideline note D21: | Pharmacogenetics testing for psychiatric medication management |

## Guideline notes for health services that appear on the Prioritized List

|                    |   |
|--------------------|---|
| Guideline note 1:  | Routine cervical cancer screening   |
| Guideline note 2:  | Fetoscopic surgery  |
| Guideline note 3:  | Prophylactic treatment for prevention of breast cancer in high risk women |
| Guideline note 4:  | Tobacco dependence, including during pregnancy                            |
| Guideline note 5:  | Obesity and overweight  |
| Guideline note 6:  | Rehabilitative and habilitative therapies                                 |
| Guideline note 7:  | Erythropoiesis-stimulating agent (ESA) guideline                          |
| Guideline note 8:  | Bariatric surgery   |
| Guideline note 9:  | Wireless capsule endoscopy  |
| Guideline note 10: | Central serous chorioretinopathy and posterior cyclitis                   |
| Guideline note 11: | Colony stimulating factor (CSF) guidelines                                |
| Guideline note 12: | Treatment of cancer with little or no benefit                             |
| Guideline note 13: | Hemangiomas, complicated  |
| Guideline note 14: | Second bone marrow transplants  |
| Guideline note 15: | Heterotopic bone formation  |
| Guideline note 16: | Proton beam therapy for cancer  |
| Guideline note 17: | Preventive dental care  |
| Guideline note 18: | Ventricular assist devices  |
| Guideline note 19: | PET scan guidelines   |
| Guideline note 20: | Attention deficit/hyperactivity disorders in children                     |
| Guideline note 21: | Severe inflammatory skin disease  |
| Guideline note 22: | Planned cesarean delivery   |
| Guideline note 23: | Colon cancer surveillance   |
| Guideline note 24: | Complicated hernias   |
| Guideline note 25: | Stem cell transplantation for neuroblastoma                               |
| Guideline note 26: | Breast cancer surveillance  |
| Guideline note 27: | Sleep apnea   |



|                    |  |
|--------------------|--|
| Guideline note 28: | Trochanteric bursitis  |
| Guideline note 29: | Tympanostomy tubes in acute otitis media   |
| Guideline note 30: | Testicular cancer  |
| Guideline note 31: | Cochlear implantation  |
| Guideline note 32: | Cataract   |
| Guideline note 33: | Nitrous oxide for labor pain   |
| Guideline note 34: | Extraction of impacted wisdom teeth  |
| Guideline note 35: | Sinus surgery  |
| Guideline note 36: | Adenotonsillectomy for indications other than obstructive sleep apnea            |
| Guideline note 37: | Surgical interventions for conditions of the back and spine other than scoliosis |
| Guideline note 38: | Subtalar arthroereisis   |
| Guideline note 39: | Endometriosis and adenomyosis  |
| Guideline note 40: | Uterine leiomyoma  |
| Guideline note 41: | Scoliosis  |
| Guideline note 42: | Chemodenervation for chronic migraine  |
| Guideline note 43: | Lymphedema   |
| Guideline note 44: | Menstrual bleeding disorders   |
| Guideline note 45: | Chemodenervation of the bladder  |
| Guideline note 46: | Age-related macular degeneration   |
| Guideline note 47: | Urinary incontinence   |
| Guideline note 48: | Frenulectomy/frenulotomy   |
| Guideline note 49: | Wearable cardiac defibrillators  |
| Guideline note 50: | Pelvic organ prolapse surgery  |
| Guideline note 51: | Chronic otitis media with effusion   |
| Guideline note 52: | Chronic anal fissure   |
| Guideline note 53: | Basic periodontics   |
| Guideline note 54: | Conduct disorder   |
| Guideline note 55: | Pelvic pain syndrome   |
| Guideline note 56: | Non-interventional treatments for conditions of the back and spine               |
| Guideline note 57: | Mild psoriasis   |
| Guideline note 58: | Impulse disorders  |
| Guideline note 59: | Dysmenorrhea   |
| Guideline note 60: | Opioids for conditions of the back and spine                                     |
| Guideline note 61: | Hospitalization for acute viral infections                                       |
| Guideline note 62: | Negative pressure wound therapy  |
| Guideline note 63: | Hydrocele repair   |
| Guideline note 64: | Pharmacist medication management   |
| Guideline note 65: | Telephone and email consultations  |
| Guideline note 66: | Cervical dysplasia   |



|                     |   |
|---------------------|---|
| Guideline note 67:  | Enzyme replacement therapy  |
| Guideline note 68:  | Hysteroscopic bilateral fallopian tube occlusion  |
| Guideline note 69:  | Electroconvulsive therapy (ECT)   |
| Guideline note 70:  | Heart-kidney transplants  |
| Guideline note 71:  | Hip resurfacing   |
| Guideline note 72:  | Congenital urologic conditions  |
| Guideline note 73:  | Penile anomalies  |
| Guideline note 74:  | Growth hormone treatment  |
| Guideline note 75:  | Applied behavior analysis for autism spectrum disorder  |
| Guideline note 76:  | Diagnostic testing for liver fibrosis to guide treatment of hepatitis C in non-cirrhotic patients |
| Guideline note 77:  | TIPS procedure  |
| Guideline note 78:  | Hepatic metastases  |
| Guideline note 79:  | Breast reconstruction   |
| Guideline note 80:  | Repair of nose tip  |
| Guideline note 81:  | Buerger's disease   |
| Guideline note 82:  | Early intervention for psychosis  |
| Guideline note 83:  | Hip core decompression  |
| Guideline note 84:  | Medical nutrition therapy for epilepsy  |
| Guideline note 85:  | Elective induction of labor   |
| Guideline note 86:  | Organic mental disorders  |
| Guideline note 87:  | Influenza   |
| Guideline note 88:  | Use of progesterone containing IUDs for non-contraceptive indications                             |
| Guideline note 89:  | Revascularization for chronic stable angina   |
| Guideline note 90:  | Cognitive rehabilitation  |
| Guideline note 91:  | Caries arresting medicament application   |
| Guideline note 92:  | Acupuncture   |
| Guideline note 93:  | Implantable GNRH analog therapy   |
| Guideline note 94:  | Pectus excavatum  |
| Guideline note 95:  | Immune modifying therapies for multiple sclerosis   |
| Guideline note 96:  | Treatment of benign neoplasm of urinary organs  |
| Guideline note 97:  | Management of acromioclavicular joint sprain  |
| Guideline note 98:  | Significant injuries to ligaments, tendons and menisci  |
| Guideline note 99:  | Routine prenatal ultrasound   |
| Guideline note 100: | Smoking and spinal fusion   |
| Guideline note 101: | Artificial disc replacement   |
| Guideline note 102: | Repetitive transcranial magnetic stimulation  |
| Guideline note 103: | Bone anchored hearing aids  |
| Guideline note 104: | Viscosupplementation of the knee  |
| Guideline note 105: | Mediastinitis   |

|                     |  |
|---------------------|--|
| Guideline note 106: | Preventive services  |
| Guideline note 107: | Hyperbaric oxygen  |
| Guideline note 108: | Continuous blood glucose monitoring                                      |
| Guideline note 109: | Vertebroplasty, kyphoplasty, and sacroplasty                             |
| Guideline note 110: | Chronic pelvic inflammatory conditions                                   |
| Guideline note 111: | Intra-aortic balloon pumps   |
| Guideline note 112: | Lung volume reduction surgery  |
| Guideline note 113: | Diseases of lips   |
| Guideline note 114: | Femoroacetabular impingement syndrome                                    |
| Guideline note 115: | Extracorporeal photophoresis   |
| Guideline note 116: | Intraocular steroid treatments   |
| Guideline note 117: | Removal of tori and excision of hyperplastic tissue                      |
| Guideline note 118: | Obstructive sleep apnea diagnosis and treatment for children             |
| Guideline note 119: | Carotid endarterectomy   |
| Guideline note 120: | Pediatric trigger thumb  |
| Guideline note 121: | Concussion and post concussion syndrome                                  |
| Guideline note 122: | Oral health risk assessment in medical settings                          |
| Guideline note 123: | Dental fillings for posterior teeth                                      |
| Guideline note 124: | Alcohol septal ablation  |
| Guideline note 125: | Carotid artery stenting  |
| Guideline note 126: | Applied behavior analysis interventions for self-injurious behavior      |
| Guideline note 127: | Gender dysphoria   |
| Guideline note 128: | Foreign bodies in the GI tract   |
| Guideline note 129: | Fecal incontinence   |
| Guideline note 130: | Blepharoplasty   |
| Guideline note 131: | Hypotony   |
| Guideline note 132: | Acne conglobata  |
| Guideline note 133: | Acute peripheral motor and digital nerve injury                          |
| Guideline note 134: | Neonatal nasolacrimal duct obstruction                                   |
| Guideline note 135: | Fibromyalgia   |
| Guideline note 136: | Collapsed vertebra   |
| Guideline note 137: | Benign bone tumors   |
| Guideline note 138: | Obstructive and reflux uropathy  |
| Guideline note 139: | Frenotomy for tongue-tie in newborns                                     |
| Guideline note 140: | Breastfeeding support and supplies                                       |
| Guideline note 141: | Laryngeal stenosis or paralysis; dysphonia                               |
| Guideline note 142: | Stereotactic body radiation therapy                                      |
| Guideline note 143: | Treatment of unilateral hearing loss                                     |
| Guideline note 144: | Proton pump inhibitor therapy for gastroesophageal reflux disease (GERD) |

|                     |  |
|---------------------|--|
| Guideline note 145: | Treatments for benign prostate enlargement with lower urinary tract symptoms                                     |
| Guideline note 146: | Ablation procedures for atrial fibrillation  |
| Guideline note 147: | IVC filters for active pulmonary embolism(PE)/deep vein thrombosis (DVT)   |
| Guideline note 148: | Biomarker tests of cancer tissue   |
| Guideline note 149: | Sclerotherapy of fluid collections   |
| Guideline note 150: | Fetal MRI  |
| Guideline note 151: | Cardiac transplant genetic testing for transplant rejection  |
| Guideline note 152: | Unspecified conduct disorder   |
| Guideline note 153: | Planned out-of-hospital birth  |
| Guideline note 154: | Ear drum repair  |
| Guideline note 155: | Electric tumor treatment fields for glioblastoma   |
| Guideline note 156: | Encounter for desensitization to allergens   |
| Guideline note 157: | Wigs   |
| Guideline note 158: | Hallux rigidus   |
| Guideline note 159: | Smoking and surgical treatment of erectile dysfunction   |
| Guideline note 160: | Congenital muscular torticollis  |
| Guideline note 161: | Sacroiliac anesthetic injections and sacroiliac joint fusion   |
| Guideline note 162: | Long-acting reversible contraceptive (LARC) placement  |
| Guideline note 163: | Skin substitutes for chronic skin ulcers   |
| Guideline note 164: | Percutaneous repair of paravalvular leaks  |
| Guideline note 165: | Fecal microbiota transplant  |
| Guideline note 166: | Breast reduction surgery for macromastia   |
| Guideline note 167: | Cholecystitis  |
| Guideline note 168: | Treatments with marginal clinical benefit or low cost-effectiveness for certain conditions                       |
| Guideline note 169: | Treatments that have no clinically important benefit or have harms that outweigh benefits for certain conditions |

# Appendix D: Evidence-based reports

Coverage guidances are evidence-based reports that include recommendations to payers and providers on Oregonians' use of health resources. Recently, HERC added a new kind of evidence report, addressing multisector interventions. These reports address interventions outside the clinical delivery system that may affect health outcomes. Note that multisector interventions are not required Oregon Health Plan benefits; they are appended to the Prioritized List for informational purposes only.

The Health Evidence Review Commission approved the following evidence-based reports from August 2015 through March 2017 (approval date noted in parentheses). After approval, reports have in the past been reviewed every two years to determine if new evidence would result in a change in recommendation. Those reports reaffirmed from a re-review are highlighted with an asterisk.

In the future, to better use staff resources, evidence-based reports will be updated only when requested by interested parties or when staff otherwise becomes aware of the need for an update. Where indicated, the new report resulted in approved changes to the Prioritized List. The "List changes" column in the table below indicates whether changes to the Prioritized List were approved between August 2015 and March 2017 in conjunction with these coverage guidance approvals. Note that no list changes resulted from topics that were re-reviewed, but most of these coverage guidances resulted in list changes when they were initially approved.

## Evidence-based status

| Evidence-based report   | Approval date          | List changes | Report type   |
|---|------------------------|--------------|---|
| Biomarker Tests of Cancer Tissue for Prognosis and Potential Response to Treatment              | 8/13/2015              | Yes          | Coverage guidance   |
| Planned Out-of-hospital Birth   | 11/12/2015             | Yes          | Coverage guidance   |
| Vertebroplasty, Kyphoplasty and Sacroplasty*  | 1/14/2016              | No           | Coverage guidance   |
| Self-Monitoring of Blood Glucose for Type 1 & 2 Diabetes*                                       | 1/14/2016              | No           | Coverage guidance   |
| Proton Beam Therapy   | 1/14/2016              | Yes          | Coverage guidance   |
| PET Scan for Breast Cancer*   | 1/14/2016              | No           | Coverage guidance   |
| Nitrous Oxide Use for Labor Pain Management   | 1/14/2016              | Yes          | Coverage guidance   |
| Neuroimaging for Headache*  | 1/14/2016              | No           | Coverage guidance   |
| MRI for Breast Cancer Diagnosis*  | 1/14/2016              | No           | Coverage guidance   |
| Induction of Labor*   | 1/14/2016              | No           | Coverage guidance   |
| Cervical Cancer Screening*  | 1/14/2016<br>(retired) | No           | Coverage guidance   |
| Carotid Endarterectomy*   | 1/14/2016              | No           | Coverage guidance   |
| Tobacco Cessation during Pregnancy  | 8/11/2016              | Yes*†        | Coverage guidance/<br>multisector<br>interventions report |
| Noninvasive Testing for Liver Fibrosis in patients with Chronic Hepatitis C                     | 10/6/2016              | Yes          | Coverage guidance   |
| Metabolic and Bariatric Surgery   | 10/6/2016              | Yes          | Coverage guidance   |
| Timing of Long-Acting Reversible Contraceptive Placement  | 11/10/2016             | Yes          | Coverage guidance   |
| Multisector Interventions for Obesity   | 11/10/2016             | N/A†         | Multisector<br>interventions report                       |
| Digital Breast Tomosynthesis (3D Mammography) for Breast Cancer Screening in Average Risk Women | 3/9/2017               | No           |   |

\* Recommendations included in previous report reaffirmed upon re-review.

† Multisector Interventions listed at the end of the Prioritized List but do not constitute part of the OHP benefit package.



OREGON OFFICE OF HEALTH POLICY  
PORTLAND OFFICE  
421 S.W. Oak St., Suite 850  
Portland, OR 97204  
Fax: 503-945-5872

This document can be provided upon request in an alternate format for individuals with disabilities or in a language other than English for people with limited English skills. To request this publication in another format or language, contact Jeff Scroggin, Health Policy and Analytics Division, at 541-999-6983, 711 for TTY, or email [jeff.scroggin@state.or.us](mailto:jeff.scroggin@state.or.us).